



BlueCross BlueShield  
of Alabama

---

**Name of Policy:**

**Proteomic Testing for Systemic Targeted Therapy in  
Non-Small Cell Lung Cancer**

Policy #: 570  
Category: Laboratory

Latest Review Date: May 2018  
Policy Grade: B

---

**Background/Definitions:**

*As a general rule, benefits are payable under Blue Cross and Blue Shield of Alabama health plans only in cases of medical necessity and only if services or supplies are not investigational, provided the customer group contracts have such coverage.*

*The following Association Technology Evaluation Criteria must be met for a service/supply to be considered for coverage:*

- 1. The technology must have final approval from the appropriate government regulatory bodies;*
- 2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes;*
- 3. The technology must improve the net health outcome;*
- 4. The technology must be as beneficial as any established alternatives;*
- 5. The improvement must be attainable outside the investigational setting.*

*Medical Necessity means that health care services (e.g., procedures, treatments, supplies, devices, equipment, facilities or drugs) that a physician, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury or disease or its symptoms, and that are:*

- 1. In accordance with generally accepted standards of medical practice; and*
- 2. Clinically appropriate in terms of type, frequency, extent, site and duration and considered effective for the patient's illness, injury or disease; and*
- 3. Not primarily for the convenience of the patient, physician or other health care provider; and*
- 4. Not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.*

## **Description of Procedure or Service:**

Proteomic testing has been proposed as a way to predict survival outcomes, as well as the response-to and selection-of targeted therapy for patients with non-small cell lung cancer (NSCLC). One commercially-available test, the (the VeriStrat® assay [Biosesix, Boulder CO]) has been investigated as a predictive marker for response to epidermal growth factor receptor (*EGFR*) tyrosine kinase inhibitors (TKIs).

## **Non-Small-Cell Lung Cancer**

Lung cancer is the leading cause of cancer death in the United States, with an estimated 234,030 new cases and 154,050 deaths due to the disease in 2018. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and includes nonsquamous carcinoma (adenocarcinoma, large cell carcinoma, other cell types) and squamous cell carcinoma.

## **Diagnosis**

The stage at which lung cancer is diagnosed has the greatest impact on prognosis. Localized disease confined to the primary site has a 55.6% relative 5-year survival but accounts for only 16% of lung cancer cases at diagnosis. Mortality increases sharply with advancing stage. Metastatic lung cancer has a relative 5-year survival of 4.5%. Overall, advanced disease; defined as regional involvement and metastatic account for approximately 80% of cases of lung cancer at diagnosis. These statistics are mirrored for the population of NSCLC with 85% of cases presenting as advanced disease and up to 40% of patients with metastatic disease.

In addition to tumor stage; age, sex, and performance status are independent prognostic factors for survival particularly in early-stage disease. Wheatley-Price et al (2010) reported on a retrospective pooled analysis of 2349 advanced NSCLC patients from 5 randomized chemotherapy trials. Women had a higher response rate to platinum-based chemotherapy than men. Greater overall survival (OS) than men were among those with adenocarcinoma histology. A small survival advantage exists for squamous cell carcinoma over non-bronchiolar nonsquamous histology.

The oncology clinical care and research community use standard measures of performance status: Eastern Cooperative Oncology Group scale and Karnofsky Performance Scale.


## **Treatment**

Treatment approaches are multimodal and generally include surgery, radiotherapy, and chemotherapy (either alone or in combination with another treatment, depending on disease stage and tumor characteristics). The clinical management pathway for stage I or II NSCLC is shown in Figure 1.

The clinical management pathway for newly diagnosed advanced NSCLC is shown in Figure 2. Treatment recommendations are based on the overall health or performance status of the patient as well as the presence or absence of a treatment-sensitizing genetic variant. The latter is used to select for targeted therapy or platinum-based chemotherapy.


The clinical management pathway for advanced NSCLC after progression on first-line treatment or recurrence is shown in Figure 3. Treatment options are based on objective response to prior therapy, duration of response, as well as the type of and duration of prior therapy (either targeted therapy or chemotherapy).

**Figure 1. Clinical Management Pathways for Newly Diagnosed Stage I or II NSCLC**




NSCLC: non-small-cell lung cancer; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; RT: radiotherapy; SBRT: stereotactic body radiotherapy.

**Figure 2. Clinical Management Pathways for Newly Diagnosed Advanced NSCLC**



NSCLC: non-small-cell lung cancer; ORR: overall response rate; OS: overall survival; PD-L1: programmed death-ligand 1; PFS: progression-free survival; TT: targeted treatment.

**Figure 3. Clinical Management Pathways for Advanced NSCLC That Has Progressed**



NSCLC: non-small-cell lung cancer; ORR: overall response rate; OS: overall survival; PD-L1: programmed death-ligand 1; PFS: progression-free survival; TT: targeted treatment.

### Genomic Alterations

Several common genetic alterations in NSCLC have been targets for drug therapy, the most well-established of which are tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (*EGFR*) and crizotinib targeting the anaplastic lymphoma kinase (*ALK*) gene rearrangement.

#### *EGFR Variants*

*EGFR*, a receptor tyrosine kinase (TK), is frequently overexpressed and activated in NSCLC. Drugs that inhibit *EGFR* signaling either prevent ligand binding to the extracellular domain (monoclonal antibodies) or inhibit intracellular TK activity (small molecule TKIs). These targeted therapies dampen signal transduction through pathways downstream to the *EGFR*, such as the RAS/RAF/MAPK cascade. RAS proteins are G-proteins that cycle between active and inactive forms in response to stimulation from cell surface receptors such as *EGFR*. Further, RAS proteins act as binary switches between cell surface *EGFR* and downstream signaling pathways and those pathways play a crucial role in cancer cell proliferation, invasion, metastasis, and stimulation of neovascularization.

Variants in two regions of the *EGFR* gene, including small deletions in exon 19 and a point variant in exon 21 (L858R) appear to predict tumor response to tyrosine kinase inhibitors (TKIs) such as erlotinib. The prevalence of *EGFR* variants in NSCLC varies by population, with the highest prevalence in non-smoking, Asian women, with adenocarcinoma; for that subpopulation, *EGFR* variants have been reported to be as high as 30%-50%. The reported prevalence of *EGFR* variants in lung adenocarcinoma patients in the U.S. is approximately 15%.

#### *ALK Variants*

In 2% to 7% of NSCLC patients in the US, tumors express a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (*EML4*) gene and the anaplastic lymphoma kinase gene (*EML4-ALK*) which is created by an inversion on chromosome 2p. The *EML4* fusion leads to ligand-independent activation of *ALK*, which encodes a receptor TK whose precise cellular function is not completely understood. *EML4-ALK* variants are more common in never-smokers or light smokers, tend to be associated with younger age of NSCLC onset, and typically do not occur in conjunction with *EGFR* variants.

Testing for the *EML4-ALK* fusion gene in patients with adenocarcinoma-type NSCLC is used to predict response to the small molecule TKI crizotinib.

#### *Other Genetic Variants*

Other genetic variants, identified in subsets of patients with NSCLC, are summarized in Table 1. The role of testing for these variants to help select targeted therapies for NSCLC is less well-established than for *EGFR* variants.

**Table 1: Non-EGFR Variants in NSCLC**

Gene	Gene Function	Estimated Variants Prevalence in NSCLC	Patient and Tumor Characteristics
<i>KRAS</i>	Encodes RAS proteins; mutations associated with constitutively-activated protein.	20-30%	<ul style="list-style-type: none"> <li>• Adenocarcinomas</li> <li>• Heavy smokers</li> </ul>
<i>ROS1</i>	Encodes a receptor tyrosine kinase in the insulin receptor family.	0.9-3.7%	<ul style="list-style-type: none"> <li>• Adenocarcinomas</li> <li>• Never smokers</li> </ul>
<i>RET</i>	Proto-oncogene that encodes a receptor tyrosine kinase growth factor.	0.6-2%	
<i>MET</i>	Oncogene that encodes a receptor tyrosine kinase that is activated in response to binding of hepatocyte growth factor.	2-4% of previously-untreated NSCLC; 5-20% of patients with acquired resistance to EGFR TKIs	Patients with acquired resistance to EGFR TKIs
<i>BRAF</i>	Serine-threonine kinase downstream from RAS in RAS-RAF-ERK-MAPK pathway	1-3% of adenocarcinomas	Heavy smokers
<i>HER</i>	HER ( <i>EGFR</i> ) family of TK receptors; dimerizes with <i>EGFR</i> family members when activated.	1-2% of NSCLC	<ul style="list-style-type: none"> <li>• Adenocarcinomas</li> <li>• Nonsmoking women</li> </ul>
<i>PIK3CA</i>	Intracellular signaling pathway	~4% of NSCLC	

*EGFR*: epidermal growth factor receptor; *HER*: human epidermal growth factor receptor; NSCLC: non-small cell lung cancer; TK: tyrosine kinase; TKI: tyrosine kinase inhibitor.

### Targeted Treatment Options

#### *EGFR-Selective Small Molecule TKIs*

Three orally administered *EGFR*-selective small molecule TKIs have been identified for use in treating NSCLC: gefitinib (Iressa®, AstraZeneca [Cambridge, United Kingdom]), erlotinib (Tarceva®, OSI Pharmaceuticals [Farmingdale, NY]), and afatinib (Gilotrif™, Boehringer Ingelheim [Ingelheim am Rhein, Germany]). (see Table 2). Although the Food and Drug Administration (FDA) approved gefitinib in 2004, a Phase 3 trial suggested gefitinib was not associated with a survival benefit. In 2003, the FDA revised gefitinib labeling, further limiting its use to patients who had previously benefitted or were currently benefiting from the drug; no new patients were to be given gefitinib. However, in July 2015, the FDA approved gefitinib as first-line treatment for patients with metastatic NSCLC for patients with *EGFR*-mutated tumors. Erlotinib and afatinib also have approval by the FDA.

In 2015, osimertinib (Tagrisso; AstraZeneca), an irreversible selective *EGFR* inhibitor that targets T790M variant-positive NSCLC, received FDA approval for patients with T890M-variant-positive NSCLC who have progressed on an *EGFR* TKI.

A 2013 meta-analysis of 23 trials assessing the use of erlotinib, gefitinib, and afatinib in patients with advanced NSCLC reported improved progression free survival (PFS) in *EGFR* variant-positive patients treated with *EGFR* TKIs in the first- and second-line settings and as maintenance therapy. Comparisons were chemotherapy, chemotherapy and placebo, and placebo in the first-line, second-

line, and maintenance therapy settings. Among *EGFR* variant-negative patients, PFS was improved with *EGFR* TKIs compared with placebo for maintenance therapy but not in the first- and second-line settings. Overall survival (OS) did not differ between treatment groups in either variant-positive or variant-negative patients. Statistical heterogeneity was not reported for any outcome. Reviewers concluded that *EGFR* variant testing is indicated to guide treatment selection in NSCLC patients.

On the basis of the results of five Phase III randomized controlled trials, the American Society of Clinical Oncology recommended that patients with NSCLC who are being considered for first-line therapy with an *EGFR* TKI (patients who have not previously received chemotherapy or an *EGFR* TKI) should have their tumor tested for variants to determine whether an *EGFR* TKI or chemotherapy is the appropriate first-line therapy.

The primary target population for TKIs in NSCLC is for *EGFR* variant-positive patients with advanced NSCLC. The use of TKIs in NSCLC in *EGFR* variant-negative patients is controversial. The TITAN trial (2012) demonstrated no significant differences in OS between erlotinib and chemotherapy as second-line treatment for patients unselected on the basis of *EGFR* variant status, with fewer serious adverse events in erlotinib-treated patients. Karampeazis et al (2013) reported similar efficacy between erlotinib and standard chemotherapy (pemetrexed) for second-line therapy in patients unselected on the basis of *EGFR* variant status. By contrast, in the TAILOR trial (2013), standard chemotherapy was associated with longer OS than erlotinib for second-line therapy in patients with wild-type *EGFR*. Auliac et al (2014) compared sequential erlotinib plus docetaxel with docetaxel alone as second-line therapy among patients with advanced NSCLC and *EGFR* wild-type or unknown status. Based on a Simon's optimal two-stage design, the erlotinib plus-docetaxel strategy was rejected. Despite the rejection, it is worth noting that in the erlotinib plus docetaxel arm 18 of the 73 patients achieved PFS at 15 weeks; comparatively, in the docetaxel arm, 17 of 74 patients achieved PFS at 15 weeks.

In 2016, Cicenias et al reported results of the IUNO RCT, which compared maintenance therapy with erlotinib followed by second line chemotherapy if progression occurred to placebo followed by erlotinib if progression occurred in 643 patients with advanced NSCLC with no known *EGFR* variant. Because there were no significant differences between groups in terms of PFS, objective response rate, or disease control rate; maintenance therapy with erlotinib in patients without *EGFR* variants was not considered efficacious.

#### *Anti-EGFR Monoclonal Antibodies*

For the treatment of *KRAS*-mutated NSCLC, anti-*EGFR* monoclonal antibodies have been investigated as possible treatment options. Available anti-*EGFR* monoclonal antibodies include cetuximab and panitumumab. Neither drug has an established role in the treatment of NSCLC either as a component of initial therapy or as second-line therapy.

#### *Programmed Death Ligand 1 Inhibitors*

Some tumors, including some NSCLCs, express a programmed death ligand 1 (PD-L1) on the cell surfaces to interact with host T-cells and evade the immune system. Several humanized monoclonal antibodies have been developed to act as immune checkpoint inhibitors by interfering with this interaction, to interact with the PD-L1, block the cancer/T-cell interaction, and thus act as immune checkpoint inhibitors. Pembrolizumab, nivolumab, and atezolizumab which inhibit the PD-1 receptor, and atezolizumab, which inhibits the PD-L1, are used in NSCLC which has PD-L1 expression on its



cells. Durvalumab also targets the PD-L1 protein but is used in unresectable, stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiotherapy.

#### *Other Targeted Therapies*

Crizotinib is a novel *MET*-, *ROS-1*-, and *ALK*-TKI, and associated with improved progression-free survival in patients with advanced NSCLC who are *ALK* gene rearrangement-positive. Crizotinib is considered first-line therapy for advanced *ALK*-positive lung adenocarcinoma. Other small molecule TKIs, designed to selectively bind to and inhibit *ALK* activation, have FDA approval: ceritinib, alectinib, and brigatinib.

Proposed targeted therapies for other genetic alterations in NSCLC are trastuzumab for *HER2* variants, crizotinib for *MET* amplification and *ROS-1* rearrangement, vemurafenib and dabrafenib for *BRAF* variants and cabozantinib for *RET* rearrangements.

#### Proteomics Testing in Selecting Targeted Treatment for NSCLC

The term *proteome* refers to the entire complement of proteins produced by an organism, or cellular system and *proteomics* refers to the large-scale comprehensive study of a specific proteome. The proteome may differ from cell to cell and may vary over time and in response to selected stressors.

A cancer cell's proteome is related to its genome and genomic alterations. The proteome may be measured by mass spectrometry (MS) or protein microarray. For cancer, proteomic signatures in the tumor or bodily fluids (i.e., pleural fluid or blood) other than the tumor have been investigated as a biomarker for cancer activity.

A commercially available serum-based test (VeriStrat) has been developed and proposed to be used as a prognostic tool to predict expected survival for standard therapies used in the treatment of NSCLC. The test is also proposed to have predictive value for response to *EGFR* TKIs. The test uses matrix-assisted laser desorption ionization MS analysis, and a classification algorithm was developed on a training set of pretreatment sera from 3 cohorts (Italian A, Japan A, Japan B) totaling 139 patients with advanced NSCLC who were treated with second-line gefitinib. The classification result is either "good" or "poor. Two validation studies using pretreatment sera from 2 cohorts of patients (Italian B, Eastern Cooperative Oncology Group 3503) totaling 163 patients have been reported (see Tables 3 and 4).

This assay uses an 8-peak proteomic signature; 4 of the 8 have been identified as fragments of serum amyloid A protein 1. This protein has been found to be elevated in individuals with a variety of conditions associated with acute and chronic inflammation. The specificity for malignant biologic processes and conditions has not been determined. With industry support, Fidler et al (2018) used convenience biorepository samples to investigate 102 analytes for potential correlations between the specific peptide and protein biomarkers and VeriStrat classification.

Although the VeriStrat® MALDI-MS-based predictive algorithm has the largest body of literature associated with it, other investigators have used alternative mass spectrometry methods, such as surface-enhanced laser desorption ionization/time-of-flight mass spectrometry, and alternative predictive algorithms, to assess proteomic predictors of lung cancer risk.

Best practices for peptide measurement and guidelines for publication of peptide and protein identification have been published for the research community.

**Table 2. Targeted Treatment Options Approved by FDA**

Drug	Indication	Manufacturer	Approved	NDA/BLA
Gefitinib (Iressa®)	<ul style="list-style-type: none"> <li>• Monotherapy for locally advanced or metastatic NSCLC after failure of platinum-based and docetaxel chemotherapies</li> <li>• Revised label to limit use to patients currently benefiting or previously benefited from gefitinib</li> <li>• First-line treatment of patients with metastatic NSCLC whose tumors have <i>EGFR</i> exon 19 deletions or exon 21 (L858R) substitution variants as detected by an FDA-approved test</li> </ul>	AstraZeneca	05/03	NDA 21-399
			06/05	
			06/15	NDA 206995
Erlotinib (Tarceva®)	<ul style="list-style-type: none"> <li>• Monotherapy for treatment of patients with locally advanced or metastatic NSCLC after failure of at least 1 prior chemotherapy regimen</li> <li>• Maintenance therapy for patients with locally advanced or metastatic NSCLC whose disease has not progressed after 4 cycles of platinum-based first-line chemotherapy</li> <li>• First-line treatment of patients with metastatic (NSCLC) whose tumors have <i>EGFR</i> exon 19 deletions or exon 21 (L858R) substitution variants as detected by an FDA-approved test</li> <li>• Treatment of patients with metastatic NSCLC whose tumors have <i>EGFR</i> exon 19 deletions or exon 21 (L858R) substitution variants as detected by an FDA-approved test receiving first-line, maintenance, or second- or greater line treatment after progression following at least 1 prior chemotherapy regimen</li> </ul>	OSI Pharmaceuticals and Genentech	11/04	NDA 021743
			04/10	NDA 021743/S16
			05/13	NDA 021743/S18
			10/16	NDA 021743/S25
Afatinib (Gilotrif®)	<ul style="list-style-type: none"> <li>• First-line treatment of patients with metastatic (NSCLC) whose tumors have <i>EGFR</i> exon 19 deletions or exon 21 (L858R) substitution variants as detected by an FDA-approved test</li> <li>• Treatment of patients with metastatic, squamous, NSCLC progressing after platinum-based chemotherapy</li> <li>• Treatment of patients with NSCLC whose tumors have nonresistant <i>EGFR</i> variants as detected by an FDA-approved test, which includes additional variants other than <i>EGFR</i> exon 19 deletions or exon 21 (L858R) substitution variants</li> </ul>	Boehringer Ingelheim	07/13	NDA 201292
			04/16	NDA 201292/S7
			01/18	NDA 201292/S14
Necitumumab (Portrazza®)	<ul style="list-style-type: none"> <li>• <i>EGFR</i> antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous NSCLC</li> </ul>	Eli Lilly	11/15	BLA 125547
Osimertinib (Tagrisso®)	<ul style="list-style-type: none"> <li>• Treatment of patients with metastatic <i>EGFR</i> T790M variant-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after <i>EGFR</i> TKI</li> </ul>	AstraZeneca	11/15	NDA 208065

Drug	Indication	Manufacturer	Approved	NDA/BLA
Crizotinib (Xalkori®)	therapy <ul style="list-style-type: none"> <li>• Treatment of patients with locally advanced or metastatic NSCLC that is <i>ALK</i>-positive as detected by an FDA-approved test</li> <li>• Treatment of patients with metastatic NSCLC whose tumors are <i>ROS1</i>-positive</li> </ul>	Novartis	08/11  03/16	NDA 202570  NDA 202570/S16
Ceritinib (Zykadia®)	<ul style="list-style-type: none"> <li>• A kinase inhibitor indicated for treatment of patients with <i>ALK</i>-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib</li> </ul>	Novartis	04/14	NDA 205755
Alectinib (Alecensa®)	<ul style="list-style-type: none"> <li>• A kinase inhibitor indicated for treatment of patients with <i>ALK</i>-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib</li> <li>• A kinase inhibitor indicated for treatment of patients with <i>ALK</i>-positive metastatic NSCLC as detected by an FDA-approved test</li> </ul>	Hoffman-La Roche	12/15  11/17	NDA 208434  NDA 208434/S3
Brigatinib (Alunbrig®)	<ul style="list-style-type: none"> <li>• Treatment of patients with <i>ALK</i>-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib</li> </ul>	ARIAD	04/17	NDA 208772
Pembrolizumab (Keytruda®)	<ul style="list-style-type: none"> <li>• Treatment of patients with metastatic, PD-L1- positive NSCLC, as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy</li> <li>• Treatment of patients with metastatic NSCLC whose tumors express PD-L1 [Tumor Proportion Score (TPS) <math>\geq</math> 1%] as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy</li> <li>• Expansion of metastatic NSCLC indication to include first-line treatment of patients whose tumors have high PD-L1 expression (TPS <math>\geq</math> 50%) as determined by an FDA-approved test, with no <i>EGFR</i> or <i>ALK</i> genomic tumor aberrations</li> <li>• Use in combination with pemetrexed and carboplatin, for the first-line treatment of patients with metastatic nonsquamous, NSCLC</li> </ul>	Merck	10/15  10/16  10/16  05/17	BLA 125514/S5  BLA 125514/S8  BLA 125514/S12  BLA 125514/S16
Nivolumab (Opdivo®)	<ul style="list-style-type: none"> <li>• Treatment of patients with metastatic NSCLC with progression on or after platinum-based chemotherapy. Patients with <i>EGFR</i> or <i>ALK</i> genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving drug</li> </ul>	Bristol-Myers Squibb	10/15	BLA 125554/S005
Atezolizumab (Tecentriq®)	<ul style="list-style-type: none"> <li>• Metastatic NSCLC patients who have disease progression during or following platinum-containing chemotherapy. Patients with <i>EGFR</i> or <i>ALK</i> genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Tecentriq.</li> </ul>	Genentech	4/17	BLA 761034

Drug	Indication	Manufacturer	Approved	NDA/BLA
Durvalumab (Imfinzi®)	<ul style="list-style-type: none"> <li>Use in unresectable, stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiotherapy</li> </ul>	AstraZeneca	02/18	BLA 761069/S-002

ALK: anaplastic lymphoma kinase; BLA: biologics license application; EGFR: epidermal growth factor receptor; FDA: Food and Drug Administration; NDA: new drug application; NSCLC: non-small-cell lung cancer; PD-L1: programmed death-ligand 1; TKI: tyrosine kinase inhibitor.

**Policy:**

**The use of proteomic testing, including but not limited to the VeriStrat® assay, does not meet Blue Cross and blue Shield of Alabama’s medical criteria for coverage for all uses in the management of non-small cell lung cancer and is considered investigational.**

*Blue Cross and Blue Shield of Alabama does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Cross and Blue Shield of Alabama administers benefits based on the member’s contract and corporate medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.*

**Key Points:**

This most recent review of the literature occurred through March 31, 2018.

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

**Non-Small-Cell Lung Cancer**

Clinical Context and Test Proposed

The purpose of proteomic testing in individuals with non-small-cell lung cancer (NSCLC) who are epidermal growth factor receptor (EGFR)-negative or EGFR-status unknown NSCLC is to predict expected survival when receiving standard therapies for treatment of NSCLC. More specifically, the testing could impact the decision point for the selection of treatment based on a prediction of response to EGFR tyrosine kinase inhibitors (TKIs). That is, that the VeriStrat classification is predictive of a differential response to EGFR TKIs.

The question addressed in this evidence review is: Does proteomic testing in patients with NSCLC who have EGFR-negative or EGFR-status unknown NSCLC predict survival after receiving standard therapies and response to systemic therapy and improve health outcomes?

The following PICOTS were used to select literature to inform this review.

#### *Patients*

The relevant populations of interest are patients with EGFR-negative or EGFR-status unknown NSCLC who are newly diagnosed or who have progressed after first-line treatment.

#### *Intervention*

The test being considered is management with a serum proteomic test to predict survival and select systemic therapy.

#### *Comparator*

The following practice is currently being used: standard medical management.

#### *Outcomes*

The outcomes of interest are overall survival (OS) and progression-free survival (PFS).

#### *Time*

The timing of testing is when patients are newly diagnosed with NSCLC or have failed to respond to first-line therapy.

#### *Setting*

The test is available commercially through a single laboratory.

#### Simplifying Test Terms

There are 3 core characteristics for assessing a medical test. Whether imaging, laboratory, or other, all medical tests must be:

- Technically reliable
- Clinically valid
- Clinically useful.

Because different specialties may use different terms for the same concept, we are highlighting the core characteristics. The core characteristics also apply to different uses of tests, such as diagnosis, prognosis, and monitoring treatment.

Diagnostic tests detect presence or absence of a condition. Surveillance and treatment monitoring are essentially diagnostic tests over a time frame. Surveillance to see whether a condition develops or progresses is a type of detection. Treatment monitoring is also a type of detection because the purpose is to see if treatment is associated with the disappearance, regression, or progression of the condition.

Prognostic tests predict the risk of developing a condition in the future. Tests to predict response to therapy are also prognostic. Response to therapy is a type of condition and can be either a beneficial response or adverse response. The term predictive test is often used to refer to response to therapy. To simplify terms, we use prognostic to refer both to predicting a future condition or to predicting a response to therapy.

### Technically Reliable

Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review, and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

### Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### *Proteomic Testing in NSCLC for Disease Prognosis*

The largest body of evidence on the clinical validity of proteomic testing for NSCLC relates to its ability to predict disease outcomes.

No published studies were identified that assessed the use of VeriStrat proteomic testing in newly diagnosed stage I or II NSCLC.

For individuals with newly diagnosed advanced NSCLC without prior systemic therapy, multiple studies (Amann et al [2010], Kuiper et al [2012], Akerley et al [2013], Gautschi et al [2013], Stinchcombe et al [2013]) have assessed the use of VeriStrat (good or poor) as a prognostic test to discriminate between OS (primary outcome) and PFS (secondary outcome) outcomes. All studies were retrospective and intended to validate the extent to which the VeriStrat proteomic classification correlated with OS or PFS. Grossi et al (2017) was an observational nonrandomized study with prospective sample collection for proteomic testing before NSCLC treatment and reported PFS as the primary outcome. Grossi (2017) is the only study that included a first-line treatment consistent with current guidelines-based recommendations; platinum-doublet-based chemotherapy with cisplatin or carboplatin in combination with pemetrexed.

A summary of study characteristics and results of these 5 studies is presented in Tables 3 and 4.

The VeriStrat classification was not used to direct selection of treatment in any of the clinical trials from which the validation samples were derived. Testing for the presence of a sensitizing variant (*EGFR*) for targeted therapy with TKIs was variably performed in these studies. When testing was performed and results known as wild-type (negative) or positive, the analysis of OS and PFS was variably adjusted for variant status. The relation between VeriStrat classification and OS and PFS in populations with unknown variant status, when reported, was not analyzed. Disposition of populations with variant status “not reported” was generally not clear and could not be construed as “unknown” when wild-type or positive variant status was reported.

For individuals with advanced NSCLC who had recurrent disease or who had failed prior systemic therapy, multiple studies assessed (Taguchi et al [2007], Carbone et al [2010], Keshtgarpour et al [2016]) the use of VeriStrat as a prognostic test to discriminate between good and poor survival outcomes. All studies were retrospective and intended to validate the extent to which VeriStrat proteomic classification correlated with OS or PFS. The VeriStrat classification was not used to direct selection of treatment in any of the clinical trials from which the validation samples were derived. None of the trials from which the samples for VeriStrat proteomic classification were derived used a

therapy consistent with current guidelines-based recommendations. The populations in all 3 studies were unselected for EGFR-variant status.

A summary of study characteristics and results of these 3 studies is presented in Tables 3 and 4.

Grossi et al (2018) conducted a retrospective study that combined samples from 3 separate cohorts of treatment-naïve recurrent or advanced NSCLC patients who received platinum-based chemotherapy. One cohort, identified as Italian, is duplicative of the population reported in Grossi et al (2017). The NExUS and eLung cohorts reported data that is only referenced in abstracts in Grossi et al (2018) and, thus, is of limited value to the evidentiary appraisal of VeriStrat classification. The data imported into the publication for the PFS outcome showed that the median PFS of 5.7 months for VeriStrat “good” is included in the outer bound of the confidence interval (CI) for VeriStrat “poor” in the NExUS cohort. The median PFS of 5.1 months for VeriStrat “good” is included within the CI of VeriStrat “poor” in the eLung cohort. A summary of study characteristics and results of this study is presented in Tables 3 and 4. Table 13 summarizes the treatment regimens used in Grossi et al (2018). As noted, only the Italian cohort included from Grossi et al (2017) represents current approaches to treatment. Cetuximab does not have an established role in the treatment of NSCLC either as a component of initial therapy or as second-line therapy.

While most of the literature has focused on the use of matrix-assisted laser desorption ionization (MALDI) mass spectrometry (MS) techniques and predictive algorithms similar to those used in the VeriStrat assay, other MS techniques, and predictive algorithms have been investigated. Jacot et al (2008) used surface-enhanced laser desorption ionization/time-of-flight mass spectrometry technology in combination with a predictive algorithm to discriminate between malignant and benign disease and between good and poor outcomes. Using data from a population of 87 patients with stage III or IV NSCLC receiving conventional first-line chemotherapy and with at least 1-year follow-up available, the authors developed a predictive survival classifier to differentiate between poor prognosis (n=33; OS <12 months) and good prognosis (n=54; OS >12 months). In multivariable analysis, the proteomic-based predictor was significantly associated with OS (hazard ratio [HR], 3.45; 95% CI, 1.22 to 6.13; p<0.001).

Gaps analyses for proteomic testing in NSCLC for disease prognosis are provided in Tables 5 and 6.

The characteristics and results of additional studies using non-VeriStrat proteomic assays are summarized in Table 7.

**Table 3. Clinical Validity Study Characteristics of Proteomic Testing in NSCLC for Disease Prognosis**

Study	Study Type	N	Population	Selection Criteria	Participant Disposition
<b>VeriStrat-specific studies</b>					
Taguchi et al (2007) <sup>b</sup>	Retro	67	Sequential cohort of late-stage or recurrent NSCLC treated with single-agent gefitinib used as VS algorithm validation set.	<b>ECOG PS:</b> 29.8% grade 0; 46.3% grade 1; 23.9% grade 2	2 (3%) had stage IIA disease
Italian B validation set			<ul style="list-style-type: none"> <li>• Stage IIIA: 2 (3%)</li> <li>• Stage IIIB: 5 (7.4%)</li> <li>• Stage IV: 58 (86.6%)</li> <li>• Postoperative recurrence: 0</li> </ul>	<b>Histology:</b> 56.7% adeno; 22.4% squamous; 20.9% NOS	

Study	Study Type	N	Population	Selection Criteria	Participant Disposition
			<b>Previous Chemotherapy<sup>a</sup></b>		
			n (%)		
			0		
			13 (19.4)		
			1		
			26 (38.9)		
			2		
			15 (22.4)		
			≥3		
			4 (6.0)		
Taguchi et al (2007) ECOG 3503 validation set	Retro	96	ECOG 3503 single-arm phase 2 trial of first-line erlotinib in patients with stage IIIB or IV or recurrent NSCLC used as VS algorithm validation set. <ul style="list-style-type: none"> <li>• Stage IIIA: 0</li> <li>• Stage IIIB: 9 (9.4%)</li> <li>• Stage IV: 67 (69.8%)</li> <li>• Postoperative recurrence: 20 (20.8%)</li> </ul>	<b>ECOG PS:</b> 30.2% grade 0; 43.8% grade 1; 26.0% grade 2 <b>Histology:</b> 64.6% adeno; 11.5% squamous; 1% LCC; 22.9% NOS	20 (20.8%) had postoperative occurrence
			<b>Previous Chemotherapy<sup>a</sup></b>		
			n (%)		
			0		
			96 (100)		
Amann et al (2010) <sup>b</sup>	Retro	88	Sample of ECOG 3503 trial patients (enrolled 137) with stage IIIB or IV or recurrent NSCLC in phase 2 single-arm treatment with first-line erlotinib	<b>ECOG PS:</b> 28.4% grade 0; 46.1% grade 1; 25.5% grade 2 <b>Histology:</b> 64.7% adeno; 10.8% squamous; 1% LCC; 16.7% NOS; 6.9% other	<ul style="list-style-type: none"> <li>• 102 analyzable pretreatment biologic samples</li> <li>• Missing values: 14 (16%) VS score</li> <li>• <i>EGFR</i> exon 19 status: 61 (60%)</li> <li>• <i>EGFR</i> exon 21 status: 61 (60%)</li> <li>• No <i>EGFR</i> exon 19–positive samples</li> </ul>
Carbone et al (2010) <sup>b</sup> ; Herbst et al (2005)	Retro	35	<ul style="list-style-type: none"> <li>• Sample of phase 1/2 stage IIIB or IV (N=40): phase 1 (n=12), phase 2 (n=28) recurrent, nonsquamous NSCLC treated with open-label erlotinib and bevacizumab</li> <li>• 22 (55%) had ≥2 prior chemotherapy regimens</li> </ul>	<b>KPS:</b> 7.5% KPS 70%; 47.5% KPS 80%; 45% KPS 90% <b>Histology:</b> 75% adeno; 22.5% NOS; 2.5% other	35 available pretreatment samples with associated clinical data
Kuiper et al (2012) <sup>b</sup>	Retro	50	Sample of chemotherapy-naive patients (N=50) with pathologically documented, inoperable, locally advanced, recurrent, or metastatic NSCLC; single-arm phase 2 treated with erlotinib and sorafenib	<b>ECOG PS:</b> 40% grade 0; 60% grade 1 <b>Histology:</b> 68% adeno; 32% other	<ul style="list-style-type: none"> <li>• VS score not available or indeterminate (n=2)</li> <li>• <i>EGFR</i> status: (31) 62% WT; (7) 14% variant positive; 12 (24%) unknown</li> </ul>
Akerley et al (2013) <sup>b</sup>	Retro	42	Sample of stage IIIB or IV or recurrent nonsquamous NSCLC, with no prior chemotherapy for metastatic disease (n=40), treated with erlotinib and bevacizumab; PET and serum biomarker ancillary study (n=10)	<b>ECOG PS:</b> 26% grade 0; 74% grade 1 <b>Histology:</b> 48% adeno; 48% NOS; 4% other	<ul style="list-style-type: none"> <li>• Previously treated brain metastases allowed in expanded cohort</li> <li>• Participant accrual (n=20) prior to interim safety</li> </ul>



Study	Study Type	N	Population	Selection Criteria	Participant Disposition
					analysis; additional 20 participants accrued after safety threshold of PFS at 6 mo exceeded
					<ul style="list-style-type: none"> <li>• 42 VS assays performed on pretreatment sera</li> <li>• 28 patients received cytotoxic chemotherapy after study therapy</li> </ul>
Gautschi et al (2013) <sup>b</sup>	Retro	117	Pooled analysis of patients (158 enrolled) from SAKK19/05 (n=101) and NTR528 trials (n=47); untreated, advanced nonsquamous NSCLC, treated with first-line therapy using erlotinib and bevacizumab	<b>ECOG PS:</b> 52.9% grade 0; 42.5% grade 1; 4.6% grade 2 <b>Histology:</b> 89.7% adeno; 10.2% other	<ul style="list-style-type: none"> <li>• 117 pretreatment frozen serum available for VS assay (SAKK19/05, n=88; NTR528, n=29)</li> <li>• SAKK19/05: <i>EGFR</i> variant status: positive identification but data NR</li> <li>• NTR528: <i>EGFR</i> variant status: NR</li> </ul>
Stinchcombe et al (2013) <sup>b</sup>	Retro	98	Sample from noncomparative randomized phase 2 trial of first-line treatment for stage IIIB or IV NSCLC: <ul style="list-style-type: none"> <li>• Arm A (gemcitabine)</li> <li>• Arm B (erlotinib) or</li> <li>• Arm C (gemcitabine and erlotinib)</li> </ul>	<b>Age:</b> ≥70 y <b>ECOG PS:</b> 0-2 <b>Histology:</b> unselected	<ul style="list-style-type: none"> <li>• Treatment arm assignments stratified for sex, smoking history (never or light vs current or former use), and PS</li> <li>• 146 eligible patients received protocol therapy</li> <li>• 124 samples available for VS assay</li> <li>• 14 samples unevaluable</li> <li>• 110 samples assayed</li> </ul>
Keshtgarpour et al (2016)	Retro	49	<ul style="list-style-type: none"> <li>• Advanced-stage squamous and nonsquamous NSCLC medical record review at a single clinic (62 patients identified).</li> <li>• Determine use of VS in African-Americans</li> <li>• Determine relation between of VS and comorbidities using CCI</li> </ul>	Baseline histology and PS not reported	<ul style="list-style-type: none"> <li>• 49 cases qualified for inclusion</li> <li>• VS pretreatment: 31</li> <li>• VS during or after first-line chemotherapy</li> </ul>
Grossi et al (2017) <sup>b</sup>	Prospect	76	<ul style="list-style-type: none"> <li>• Clinically based stage IIIB NSCLC with supraclavicular lymph node metastases, or stage IV or recurrent NSCLC, chemotherapy-naive</li> </ul>	<b>ECOG PS:</b> 26% grade 0; 71% grade 1; 3% grade 2 <b>Histology:</b> 100% nonsquamous	<ul style="list-style-type: none"> <li>• 105 participants enrolled</li> <li>• 89 with nonsquamous histology included</li> </ul>

Study	Study Type	N	Population	Selection Criteria	Participant Disposition
			<ul style="list-style-type: none"> <li>To be treated with platinum doublet chemotherapy: pemetrexed plus carboplatin or cisplatin</li> </ul>		<ul style="list-style-type: none"> <li>15 with squamous histology and 1 with small cell lung cancer excluded</li> <li>6 additional patients ineligible (no treatment, consent, had surgery)</li> <li>83 eligible for VS</li> <li>7 did not receive VS classification</li> <li>Choice of chemotherapy regimen at physician discretion based on age, ECOG PS, creatinine clearance</li> </ul>
Grossi et al (2018) <sup>b</sup>	Retropective	481	<ul style="list-style-type: none"> <li>3 cohorts (NExUS, Italian, eLung) of treatment-naive recurrent or advanced NSCLC patients who received platinum-based chemotherapy</li> <li>NExUS cohort: prospective RCT of gemcitabine plus cisplatin and sorafenib vs gemcitabine plus cisplatin and placebo</li> <li>Italian: clinically based cohort treated with platinum-doublet chemotherapy</li> <li>eLung: multicenter randomized phase 2b study of cetuximab plus platinum-based chemotherapy as first-line treatment. <ul style="list-style-type: none"> <li>Arm A: carboplatin plus paclitaxel and cetuximab then maintenance cetuximab</li> <li>Arm B: carboplatin or cisplatin (investigator choice) plus gemcitabine and cetuximab then maintenance cetuximab</li> <li>Arm C: carboplatin or cisplatin (investigator choice) plus pemetrexed and cetuximab then maintenance cetuximab</li> <li>Arm C limited to squamous histology</li> <li>Delivery of 4, 5, or 6 cycles of chemotherapy at investigator discretion</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>NExUS: stage IIIB or IV NSCLC, <b>ECOG PS:</b> 0/1</li> <li><b>Histology:</b> NR</li> <li>Italian: stage IIIB NSCLC with supraclavicular lymph node metastases, or stage IV or recurrent NSCLC</li> <li><b>Histology:</b> 100% nonsquamous (Grossi et al [2017])</li> <li>eLung:</li> <li><b>ECOG PS:</b> 0/1</li> <li><b>Histology:</b> nonsquamous and squamous</li> </ul>	<ul style="list-style-type: none"> <li>NExUS: Baseline plasma samples 419 of 722 nonsquamous participants available for VS assay</li> <li>Italian: 105 participants enrolled</li> <li>89 with nonsquamous histology included</li> <li>15 with squamous histology and 1 with small cell lung cancer excluded</li> <li>6 additional patients ineligible (no treatment, consent, had surgery)</li> <li>83 eligible for VS</li> <li>7 did not receive VS classification</li> <li>eLung: 206 of 601 participants had serum available for VS assay</li> <li>203 VS assay performed</li> </ul>

adeno: adenocarcinoma; CCI: Charleston Comorbidity Index; CI: confidence interval; ECOG: European Cooperative Oncology Group; EGFR: epidermal growth factor receptor; KPS: Karnofsky Performance Status; LCC: large cell carcinoma; NOS: not otherwise

specified; NR: not reported; NSCLC: non-small-cell lung cancer; PET: positron emission tomography; PFS: progression-free survival; PS: Performance Status; TKI: tyrosine kinase inhibitor; VS: VeriStrat; WT: wild-type.

<sup>a</sup> Number of prior chemotherapy regimens.

<sup>b</sup> Industry sponsorship or collaboration.

**Table 4. Clinical Validity Study Results of Proteomic Testing in NSCLC for Disease Prognosis**

Study	Study Type	N	Patient Population	Summary of Outcomes: OS for “Good” vs “Poor” Assay	Summary of Outcomes: PFS for “Good” vs “Poor” Assay
<b>VeriStrat-specific studies</b>					
Taguchi et al (2007)	Retro	67	Sequential cohort of late-stage or recurrent NSCLC treated with single-agent gefitinib:	<b>Unadjusted</b> HR of death, 0.50 (95% CI, 0.24 to 0.78; p=0.005)	<b>Unadjusted</b> TTP: HR=0.56 (95% CI, 0.28 to 0.89; p=0.02)
Italian B validation set			<ul style="list-style-type: none"> <li>• VS “good”: 39 (58.3%)</li> <li>• VS “poor”: 27 (40.3%)</li> <li>• VS undefined: 1</li> </ul>	<b>Adjusted<sup>a</sup></b> HR of death, 0.74 (95% CI, 0.55 to 0.99; p=0.048)	
Taguchi et al (2007)	Retro	96	ECOG 3503 single-arm, phase 2 trial of first-line erlotinib in patients with stage IIIB or IV or recurrent NSCLC:	<b>Unadjusted</b> HR of death, 0.4 (95% CI, 0.24 to 0.70; p<0.001)	<b>Unadjusted</b> TTP: HR=0.53 (95% CI, 0.33 to 0.85; p=0.007)
ECOG 3503 validation set			<ul style="list-style-type: none"> <li>• VS “good”: 69 (71.9%)</li> <li>• VS “poor”: 27 (28.1%)</li> <li>• VS undefined: 0</li> </ul>	<b>Adjusted<sup>b</sup></b> HR of death, 0.53 (95% CI, 0.30 to 0.94; p=0.03)	
Amann et al (2010)		88	VS “good” (n=64), VS “poor” (n=24) <ul style="list-style-type: none"> <li>• <i>EGFR</i> exon 19 WT: 41</li> <li>• <i>EGFR</i> exon 19–positive: none identified</li> <li>• <i>EGFR</i> exon 21 WT: 38</li> <li>• <i>EGFR</i> exon 21–positive: 3</li> <li>• <i>EGFR</i> exon 21–positive and VS “good”: 2</li> <li>• <i>EGFR</i> exon 21–positive and VS “poor”: 1</li> </ul>	<b>Unadjusted</b> HR of death, 0.36 (95% CI, 0.21 to 0.60; p=0.001) <b>Adjusted (for <i>EGFR</i> status)</b> HR of death, 0.26 (95% CI, 0.06 to 1.16; p=0.08)	<b>Unadjusted</b> TTP: HR=0.51 (95% CI, 0.28 to 0.90; p=0.02)
Carbone et al (2010)	Retro	35	Treatment-experienced recurrent stage IIIB or IV, nonsquamous NSCLC treated with erlotinib and bevacizumab enrolled in a phase 1 dose-finding and phase 2 efficacy and tolerability study: <ul style="list-style-type: none"> <li>• VS “good”: 26</li> <li>• VS “poor”: 8</li> </ul>	<b>Unadjusted</b> HR of death, 0.14 (61 wk vs 24 wk; 95% CI, 0.03 to 0.58)	<b>Unadjusted</b> PFS: HR=0.045 (36 wk vs 8 wk; 95% CI, 0.008 to 0.237)
Kuiper et al (2012)	Retro	50	<ul style="list-style-type: none"> <li>• Chemotherapy-naïve patients with pathologically documented, inoperable, locally advanced, recurrent, or metastatic NSCLC, treated with erlotinib and sorafenib</li> <li>• VS classification was performed at 3 time points (pretreatment, 1 and 3 weeks after initiation therapy)</li> <li>• Pretreatment VS “good” (n=33), VS “poor” (n=15): <ul style="list-style-type: none"> <li>○ <i>EGFR</i> WT: 31</li> <li>○ <i>EGFR</i>-positive: 7</li> <li>○ <i>EGFR</i> unknown: 12</li> </ul> </li> </ul>	<b>Unadjusted using pretreatment classification only</b> <ul style="list-style-type: none"> <li>• HR for OS=0.30 (95% CI, 0.12 to 0.74; p=0.009)</li> <li>• Median OS=13.7 mo (95% CI, 12 mo to undefined) for “good” and 5.6 mo (95% CI: 1.6 to 7.6 mo) for “poor”</li> </ul>	<b>Unadjusted using pretreatment classification only</b> <ul style="list-style-type: none"> <li>• PFS: HR=0.40 (95% CI, 0.17 to 0.94; p=0.035)</li> <li>• Median PFS=5.5 mo (95% CI, 3.0 to 6.9 mo) for VS “good” vs and 2.7 mo (95% CI, 1.4 to 5.6 mo) VS “poor”</li> </ul>
Akerley et al (2013)	Retro	42	Stage IIIB or IV or recurrent nonsquamous NSCLC, with no prior chemotherapy for metastatic disease,	<b>Unadjusted on study therapy</b> HR for OS=0.27 (95% CI, 0.11 to 0.64) Median OS= 71.4 wk vs VS “good”	<b>Unadjusted on study therapy</b> • Median PFS=18.9 wk

Study	Study Type	N	Patient Population	Summary of Outcomes: OS for “Good” vs “Poor” Assay	Summary of Outcomes: PFS for “Good” vs “Poor” Assay
			treated with erlotinib and bevacizumab: <ul style="list-style-type: none"> <li>• VS “good”: 32 (76%)</li> <li>• VS “poor”: 9 (21%)</li> <li>• VS indeterminate: 1 (2%)</li> </ul>	and 19.9 wk for VS “poor” (p=0.002)	<b>Summary of Outcomes:</b> VS “good” vs 6.3 wk VS “poor” (p=0.004) <b>Study therapy plus chemotherapy</b> <ul style="list-style-type: none"> <li>• Median PFS=43.9 wk VS “good” and 6.3 wk VS “poor” (p&lt;0.001)</li> </ul>
Gautschi et al (2013)	Retro	117	Pooled analysis from SAKK19/05 and NTR528 trials: untreated, advanced nonsquamous NSCLC, treated with first-line therapy with erlotinib and bevacizumab: <ul style="list-style-type: none"> <li>• VS “good”: 87 (SAKK19/05, n=70; NTR528, n=17)</li> <li>• VS “poor”: 27 (SAKK19/05, n=16; NTR528, n=11)</li> <li>• SAKK19/05: <i>EGFR</i> variant status: positive identification but data NR</li> <li>• NTR528: <i>EGFR</i> variant status: NR</li> </ul>	<b>Unadjusted</b> <ul style="list-style-type: none"> <li>• HR=0.48 (95% CI, 0.29 to 0.78; p=0.003)</li> <li>• Median OS=13.4 mo for VS “good” and 6.2 mo for VS “poor”</li> </ul>	<b>Unadjusted</b> <ul style="list-style-type: none"> <li>• PFS: HR=0.768 (95% CI, 0.482 to 1.22; p=0.253)</li> <li>• Median PFS=4 mo for VS “good” vs 3.2 mo for VS “poor”</li> </ul>
Stinchcombe et al (2013)	Retro	98	<ul style="list-style-type: none"> <li>• 110 samples VS assayed: <ul style="list-style-type: none"> <li>○ VS “good”: 64</li> <li>○ VS “poor”: 39</li> <li>○ VS Indeterminate: 7</li> <li>○ (5 samples could not be matched with clinical data VS “good”: 1 and VS “poor”: 4)</li> </ul> </li> <li>• VS results matched with clinical data: <ul style="list-style-type: none"> <li>○ VS “good”: 63</li> <li>○ VS “poor”: 35</li> </ul> </li> <li>• Arm A (gemcitabine): <ul style="list-style-type: none"> <li>○ VS “good”: 20</li> <li>○ VS “poor”: 8</li> <li>○ 12 of 28 also received erlotinib as second-line therapy on protocol in absence of disease progression or unacceptable toxicity</li> </ul> </li> <li>• Arm B (erlotinib): <ul style="list-style-type: none"> <li>○ VS “good”: 26</li> <li>○ VS “poor”: 12</li> <li>○ 14 of 38 received second-line therapy (type NR) off protocol</li> </ul> </li> <li>• Arm C (gemcitabine and erlotinib): <ul style="list-style-type: none"> <li>○ VS “good”: 17</li> <li>○ VS “poor”: 15</li> <li>○ 13 of 32 received second-line therapy (type NR) off protocol</li> </ul> </li> </ul>	<b>Unadjusted Arm A</b> <ul style="list-style-type: none"> <li>• HR=0.82 (95% CI, 0.35 to 1.90; p=0.64)</li> <li>• Median OS VS “good”, 201 d and VS “poor”, 197 d</li> </ul> <b>Unadjusted Arm B</b> <ul style="list-style-type: none"> <li>• HR=0.40 (95% CI, 0.19 to 0.86; p=0.014)</li> <li>• Median OS VS “good”, 255 d and VS “poor”, 51 d</li> </ul> <b>Unadjusted Arm C</b> <ul style="list-style-type: none"> <li>• HR= 0.48 (95% CI, 0.23 to 1.02; p=0.051)</li> <li>• Median OS VS “good”, 302 d and VS “poor”, 106 d</li> </ul> <b>Adjusted<sup>e</sup></b> <ul style="list-style-type: none"> <li>• HR=0.53 (95% CI, 0.32 to 0.90; p=0.017)</li> </ul>	<b>Unadjusted Arm A</b> <ul style="list-style-type: none"> <li>• HR=1.21 (95% CI, 0.51 to 2.88; p=0.67)</li> <li>• Median PFS VS “good”, 133 d and VS “poor”, 137 d</li> </ul> <b>Unadjusted Arm B</b> <ul style="list-style-type: none"> <li>• HR=0.33 (95% CI, 0.16 to 0.70; p=0.002)</li> <li>• Median PFS VS “good”, 89 d and VS “poor”, 22 d</li> </ul> <b>Unadjusted Arm C</b> <ul style="list-style-type: none"> <li>• HR=0.42 (95% CI, 0.19 to 0.93; p=0.027)</li> <li>• Median PFS VS “good”, 122 d vs VS “poor”, 89 d</li> </ul> <b>Adjusted<sup>e</sup></b> <ul style="list-style-type: none"> <li>• HR=0.51 (95% CI, 0.30 to 0.86; p=0.011)</li> </ul>
Keshtgarpour et al (2016)	Retro	49	Advanced-stage squamous and nonsquamous NSCLC seen at a single clinic: <ul style="list-style-type: none"> <li>• VS “good”: 32</li> <li>• VS “poor”: 16</li> <li>• VS indeterminate: 1</li> </ul>	<b>Unadjusted for CCI</b> <ul style="list-style-type: none"> <li>• HR=0.97 (95% CI, 0.48 to 1.97; p=0.94)</li> </ul> <b>CCI adjusted model</b> <ul style="list-style-type: none"> <li>• HR=0.80 (95% CI, 0.39 to 1.64; p=0.54)</li> </ul> <b>VS “poor” on erlotinib vs</b>	

Study	Study Type	N	Patient Population	Summary of Outcomes: OS for “Good” vs “Poor” Assay	Summary of Outcomes: PFS for “Good” vs “Poor” Assay
Grossi et al (2017)	Prosp	76	<ul style="list-style-type: none"> <li>• Stage IIIB NSCLC with supraclavicular lymph node metastases, or stage IV or recurrent NSCLC, chemotherapy-naive treated with platinum doublet chemotherapy</li> <li>• Carboplatin plus pemetrexed (n=43; median age, 57 y)</li> <li>• Cisplatin plus pemetrexed (n=33; median age, 70 y)</li> <li>• VS “good”: 50 <ul style="list-style-type: none"> <li>○ VS “good”: carboplatin/pemetrexed: 28</li> <li>○ VS “good”: cisplatin/pemetrexed: 22</li> </ul> </li> <li>• VS “poor”: 26 <ul style="list-style-type: none"> <li>○ VS “poor”: carboplatin/pemetrexed: 15</li> <li>○ VS “poor”: cisplatin/pemetrexed: 11</li> </ul> </li> <li>• TKI-sensitizing variant status results: <ul style="list-style-type: none"> <li>○ EGFR WT: 67 (88%)</li> <li>○ EGFR-negative: 2 (3%)</li> <li>○ EGFR unknown: 7 (9%)</li> <li>○ ALK translocation negative: 54 (71%)</li> <li>○ ALK translocation positive: 1 (1%)</li> <li>○ ALK translocation unknown: 21 (28%)</li> <li>○ KRAS WT: 31 (41%)</li> <li>○ KRAS-positive: 29 (38%)</li> <li>○ KRAS unknown: 16 (21%)</li> </ul> </li> </ul>	<p><b>chemotherapy, CCI adjusted</b></p> <ul style="list-style-type: none"> <li>• HR=9.48 (95% CI, 1.27 to 70.81; p=0.03)</li> </ul> <p><b>Unadjusted secondary outcome in study</b></p> <ul style="list-style-type: none"> <li>• HR=0.26 (95% CI, 0.15 to 0.47; p&lt;0.001)</li> <li>• Median OS 10.8 mo in VS “good” vs 3.4 mo in VS “poor”</li> </ul> <p><b>Unadjusted secondary outcome based on treatment-defined group</b></p> <ul style="list-style-type: none"> <li>• Carboplatin plus pemetrexed vs cisplatin plus pemetrexed: <ul style="list-style-type: none"> <li>○ HR=1.64 (95% CI, 0.96 to 2.82; p=0.070)</li> <li>○ Median OS carboplatin plus pemetrexed, 6.0 mo (95% CI, 4.2 to 10.0 mo) vs cisplatin plus pemetrexed 10.3 mo (95% CI, 6.6 to 17.9 mo)</li> </ul> </li> <li>• Carboplatin plus pemetrexed VS “good” vs VS “poor”: <ul style="list-style-type: none"> <li>○ HR=0.26 (95% CI, 0.12 to 0.55; p&lt;0.001)</li> <li>○ Median OS VS “good”, 9.4 mo (95% CI, 5.0 to 15.3 mo) vs VS “poor” 3.4 mo (95% CI, 1.0 to 4.3 mo)</li> </ul> </li> <li>• Cisplatin plus pemetrexed VS “good” vs VS “poor”: <ul style="list-style-type: none"> <li>○ HR=0.25 (95% CI, 0.10 to 0.62; p=0.001)</li> <li>○ Median OS VS “good”, 17.7 mo (95% CI, 9.9 to 24.19 mo) vs VS “poor” 4.2 mo (95% CI, 2.6 to 8.9 mo)</li> </ul> </li> </ul> <p><b>Adjusted<sup>c</sup></b></p> <ul style="list-style-type: none"> <li>• HR=0.23 (95% CI, 0.12 to 0.44; p&lt;0.001)</li> </ul> <p><b>Adjusted<sup>d</sup></b></p> <ul style="list-style-type: none"> <li>• HR=0.23 (95% CI, 0.11 to 0.46; p&lt;0.001)</li> </ul>	<p><b>Unadjusted primary outcome in study</b></p> <ul style="list-style-type: none"> <li>• HR=0.36 (95% CI, 0.22 to 0.61; p&lt;0.001)</li> <li>• Median PFS=6.5 mo in VS “good” vs 1.6 mo in VS “poor”</li> </ul> <p><b>Unadjusted primary outcome based on treatment-defined group</b></p> <ul style="list-style-type: none"> <li>• Carboplatin plus pemetrexed vs cisplatin plus pemetrexed: <ul style="list-style-type: none"> <li>○ HR=1.59 (95% CI, 0.97 to 2.61; p=0.063)</li> <li>○ Median PFS carboplatin plus pemetrexed, 2.8 mo (95% CI, 2.0 to 4.0 mo) vs cisplatin plus pemetrexed 5.7 mo (95% CI, 3.8 to 8.8 mo)</li> </ul> </li> <li>• Carboplatin plus pemetrexed VS “good” vs VS “poor”: <ul style="list-style-type: none"> <li>○ HR=0.30 (95% CI, 0.14 to 0.62; p&lt;0.001)</li> <li>○ Median PFS VS “good”, 3.8 mo (95% CI, 2.7 to 8.7 mo) vs VS “poor”, 1.6 mo (95% CI, 1.0 to 2.5 mo)</li> </ul> </li> <li>• Cisplatin plus pemetrexed VS “good” vs VS “poor”: <ul style="list-style-type: none"> <li>○ HR=0.39 (95% CI, 0.18 to 0.85; p=0.014)</li> <li>○ Median PFS VS “good”, 7.9 mo (95% CI, 5.2 to 13.1 mo) vs VS “poor”, 1.7 mo (95% CI, 1.1 to 3.9 mo)</li> </ul> </li> </ul> <p><b>Adjusted<sup>c</sup></b></p> <ul style="list-style-type: none"> <li>• HR=0.32 (95% CI,</li> </ul>

Study	Study Type	N	Patient Population	Summary of Outcomes: OS for “Good” vs “Poor” Assay	Summary of Outcomes: PFS for “Good” vs “Poor” Assay
					0.18 to 0.58; p<0.001) <b>Adjusted<sup>d</sup></b> • HR=0.39 (95% CI, 0.22 to 0.71; p=0.002)
Grossi et al (2018)		481	<p>NExUS: VS assay: 202 patients in gemcitabine/cisplatin/placebo arm:</p> <ul style="list-style-type: none"> <li>• VS “good”: 136</li> <li>• VS “poor”: 66</li> </ul> <p>Italian: VS assay: 76 patients pemetrexed plus carboplatin or cisplatin:</p> <ul style="list-style-type: none"> <li>• VS “good”: 50</li> <li>• VS “good”: carboplatin plus pemetrexed: 28</li> <li>• VS “good”: cisplatin plus pemetrexed: 22</li> <li>• VS “poor”: 26</li> <li>• VS “poor”: carboplatin plus pemetrexed: 15</li> <li>• VS “poor”: cisplatin plus pemetrexed: 11</li> </ul> <p>eLung: VS assay: 203</p> <ul style="list-style-type: none"> <li>• VS “good”: 142</li> <li>• VS “good”: carboplatin plus paclitaxel and cetuximab: 52</li> <li>• VS “good”: carboplatin or cisplatin plus gemcitabine and cetuximab: 56</li> <li>• VS “good”: carboplatin or cisplatin plus pemetrexed and cetuximab :34</li> <li>• VA “poor”: 61</li> <li>• VS “poor”: carboplatin plus paclitaxel and cetuximab:27</li> <li>• VS “poor”: carboplatin or cisplatin plus gemcitabine and cetuximab: 26</li> <li>• VS “poor”: carboplatin or cisplatin plus pemetrexed and cetuximab: 8</li> </ul>	<p><b>Unadjusted <u>secondary</u> outcome in NExUS study</b></p> <ul style="list-style-type: none"> <li>• HR=0.41 (95% CI, 0.30 to 0.58; p&lt;0.001)</li> <li>• Median OS VS “good”, 14.7 mo (95% CI, 12.5 to 16.9 mo) vs VS “poor” 6.3 mo (95% CI, 5.6 to 8.1 mo)</li> </ul> <p><b>Unadjusted <u>secondary</u> outcome in Italian study</b></p> <ul style="list-style-type: none"> <li>• HR=0.26 (95% CI, 0.15 to 0.47; p&lt;0.001)</li> <li>• Median OS=10.8 mo (95% CI, 7.8 to 17.7 mo) in VS “good” vs 3.4 mo (2.4 to 4.3 mo) in VS “poor”</li> </ul> <p><b>Unadjusted <u>secondary</u> outcome in eLung study</b></p> <ul style="list-style-type: none"> <li>• HR=0.51 (95% CI, 0.37 to 0.71; p&lt;0.001)</li> <li>• Median OS=10.9 mo (95% CI, 9.5 to 12.9 mo) VS “good” vs 6.4 mo (95% CI, 4.0 to 9.0 mo) VS “poor”</li> </ul>	<p><b>Unadjusted <u>primary</u> outcome in NExUS study</b></p> <ul style="list-style-type: none"> <li>• HR=0.51 (95% CI, 0.37 to 0.71; p&lt;0.001)</li> <li>• Median PFS VS “good”, 5.7 mo (95% CI, 5.5 to 6.9 mo) vs VS “poor”, 4.6 mo (95% CI, 4.1 to 5.7 mo)</li> </ul> <p><b>Unadjusted <u>primary</u> outcome in Italian study</b></p> <ul style="list-style-type: none"> <li>• HR=0.36 (95% CI, 0.22 to 0.61; p&lt;0.001)</li> <li>• Median PFS=6.5 mo (95% CI, 3.9 to 8.8 mo) VS “good” vs 1.6 mo (95% CI, 1.1 to 2.5 mo) VS “poor”</li> </ul> <p><b>Unadjusted <u>primary</u> outcome in eLung study</b></p> <ul style="list-style-type: none"> <li>• HR=0.72 (95% CI, 0.53 to 0.97)</li> <li>• Median PFS=5.1 mo (95% CI, 4.2 to 5.7 mo) VS “good” vs 3.6 mo (95% CI, 2.7 to 5.3 mo) VS “poor”</li> </ul>

CI: confidence interval; ECOG: European Cooperative Oncology Group; *EGFR*: epidermal growth factor receptor; HR: hazard ratio; MALDI: matrix-assisted laser desorption ionization; MS: mass spectrometry; NSCLC: non-small-cell lung cancer; OS: overall survival; PFS: progression-free survival; PS: Performance Status; TKI: tyrosine kinase inhibitor; TTP: time to progression; VS: VeriStrat; WT: wild-type.

<sup>a</sup> Adjusted based on age, performance status, sex, histology, smoking history, and MALDI-MS classification.

<sup>b</sup> Adjusted based on age, number of involved sites, prior weight loss, histology, and MALDI-MS classification.

<sup>c</sup> Adjusted based on clinical characteristics: VS classification, sex, smoking status (ever vs never), ECOG PS (≥1 vs 0), *KRAS* status (mutant vs WT or unknown), *KRAS* (known vs unknown), maintenance (yes vs no).

<sup>d</sup> Adjusted based on clinical characteristics and treatment: VS classification, sex, cisplatin/pemetrexed vs carboplatin/pemetrexed smoking status (ever vs never), ECOG PS (≥1 vs 0), *KRAS* status (mutant vs WT or unknown), *KRAS* (known vs unknown), maintenance (yes vs no).

<sup>e</sup> Adjusted for VS status, histology (other histologies vs adenocarcinoma), race (nonwhite vs white), sex (female vs male), treatment arm (erlotinib vs gemcitabine), treatment arm (gemcitabine/erlotinib vs gemcitabine), smoking history (never vs ever), performance status (2 vs 0 or 1), stage IV vs IIIb.

**Table 5. Clinical Validity Relevance Gaps for Proteomic Testing in NSCLC for Disease Prognosis**

Study	Population	Intervention	Comparator	Outcomes	Follow-Up
Taguchi et al (2007) Italian B	1.Population unselected for	Other related:	3.Clinical assessment of	1. VeriStrat classification not	

Study	Population	Intervention	Comparator	Outcomes	Follow-Up
validation set	<i>EGFR</i> variant status	<ul style="list-style-type: none"> <li>Identity of proteins that make up the MALDI-MS features still being investigated at time of publication</li> </ul>	prognosis not used	used to direct therapy Other related: <ul style="list-style-type: none"> <li>Decision model based on outdated clinical pathway</li> </ul>	
Taguchi et al (2007) ECOG 3503 validation set	1. Population unselected for <i>EGFR</i> variant status 2. 20 (20.8%) of participants had postoperative recurrence which may be an indicator of earlier stage at diagnosis	Other related: <ul style="list-style-type: none"> <li>Identity of proteins that make up the MALDI-MS features still being investigated at time of publication</li> </ul>	3. Clinical assessment of prognosis not used	1. VeriStrat classification not used to direct therapy Other related: <ul style="list-style-type: none"> <li>Decision model based on outdated clinical pathway</li> </ul>	
Amann et al (2010)	1. <i>EGFR</i> variant status unknown excluded 4. Use of erlotinib (or other TKIs) in <i>EGFR</i> variant–negative population no longer accepted treatment approach 5. 90 (88.2%) with multisite metastatic disease; 55 (54%) had prior radiotherapy or surgery	Other related: <ul style="list-style-type: none"> <li>Identity of proteins that make up the MALDI-MS features still being investigated at time of publication</li> </ul>	3. Clinical assessment of prognosis not used	1. VeriStrat classification not used to direct therapy Other related: <ul style="list-style-type: none"> <li>Decision model based on outdated clinical pathway</li> </ul>	
Carbone et al (2010)	1. No determination of <i>EGFR</i> variant status 4. Study population participating in phase 1/2 study 4. Use of erlotinib (or other TKIs) in <i>EGFR</i> variant negative or unknown population no longer accepted treatment approach 4. Use of combination <i>EGFR</i> (erlotinib) and VEGF inhibition (bevacizumab) not currently accepted treatment approach	Other related: <ul style="list-style-type: none"> <li>Identity of proteins that make up the MALDI-MS features still being investigated at time of publication</li> </ul>	3. Clinical assessment of prognosis not used	1. VeriStrat classification not used to direct therapy Other related: <ul style="list-style-type: none"> <li>Decision model based on outdated clinical pathway</li> </ul>	
Kuiper et al	4. Use of erlotinib	Other related:	3. Atypical	1. VeriStrat	

Study	Population	Intervention	Comparator	Outcomes	Follow-Up
(2012)	(or other TKIs) in <i>EGFR</i> variant–negative or unknown population no longer accepted treatment approach 4. Use of combination <i>EGFR</i> (erlotinib) and VEGF inhibition (sorafenib) not currently accepted treatment approach	<ul style="list-style-type: none"> <li>Identity of proteins that make up the MALDI-MS features still being investigated at time of publication</li> </ul>	clinical assessment tool used	classification not used to direct therapy Other related: <ul style="list-style-type: none"> <li>Decision model based on outdated clinical pathway</li> <li>No outcome reported for <i>EGFR</i> variant status unknown</li> </ul>	
Akerley et al (2013)	1. Participants may have received prior adjuvant chemotherapy 4. Use of combination <i>EGFR</i> (erlotinib) and VEGF inhibition (bevacizumab) not currently accepted treatment approach	Other related: <ul style="list-style-type: none"> <li>Identity of proteins that make up the MALDI-MS features still being investigated at time of publication</li> </ul>	3.Clinical assessment of prognosis not used	1. VeriStrat classification not used to direct therapy 3.Survival of participants without VeriStrat assay reported as not different but not data provided	
Gautschi et al (2013)	4. Use of combination <i>EGFR</i> (erlotinib) and VEGF inhibition (bevacizumab) not currently accepted treatment approach	Other related: <ul style="list-style-type: none"> <li>Identity of proteins that make up the MALDI-MS features still being investigated at time of publication</li> </ul>	3.Clinical assessment of prognosis not used	1. VeriStrat classification not used to direct therapy Other related: <ul style="list-style-type: none"> <li>Decision model based on outdated clinical pathway</li> </ul>	
Stinchcombe et al (2013)	1.Population unselected for <i>EGFR</i> variant status 2. Participants in 2 arms received treatment off protocol 4. Use of erlotinib (or other TKIs) in <i>EGFR</i> variant negative or unknown population no longer accepted treatment approach	Other related: <ul style="list-style-type: none"> <li>Identity of proteins that make up the MALDI-MS features still being investigated at time of publication</li> </ul>	3.Clinical assessment of prognosis not used	1.VeriStrat classification not used to direct therapy Other related: <ul style="list-style-type: none"> <li>Decision model based on outdated clinical pathway</li> </ul>	
Keshtgarpour et al (2016)	1. No determination of <i>EGFR</i> variant status 1. Participants may have received prior	Other related: <ul style="list-style-type: none"> <li>Identity of proteins that make up the MALDI-MS</li> </ul>	3.Clinical assessment of prognosis not used	Other related: <ul style="list-style-type: none"> <li>Decision model based on outdated clinical pathway</li> </ul>	



Study	Population	Intervention	Comparator	Outcomes	Follow-Up
	first-line chemotherapy 4. Use of erlotinib (or other TKIs) in <i>EGFR</i> variant negative or unknown population no longer accepted treatment approach	features still being investigated at time of publication			
Grossi et al (2017)	3. Median age (57 y) of patients in cisplatin plus pemetrexed arm significantly younger than median age (70 y) in carboplatin plus pemetrexed arm	Other related: • Identity of proteins that make up the MALDI-MS features still being investigated at time of publication	3. Clinical assessment of prognosis not used	1. VeriStrat classification not used to direct therapy 2. Inclusion of <i>KRAS</i> variant/exclusion of <i>EGFR</i> and <i>ALK</i> testing results in adjusted analyses appears to be potential new decision model Other related: • No outcome reported for <i>EGFR</i> variant status unknown • No outcomes reported for <i>EGFR</i> wild-type • No outcomes reported for <i>ALK</i> variant status • Range of values for median OS and PFS not reported in this publication but reported in Grossi et al (2018)	
Grossi et al (2018)	1. NExUS cohort reference is abstract only 1. eLung cohort reference is abstract only 2. NExUS cohort reference is abstract only 2. eLung cohort reference is abstract only 4. eLung cohort results based on treatment	• Other related: • Identity of the proteins that make up the MALDI-MS features still being investigated at the time of publication		1. VeriStrat classification not used to direct therapy • Other related- decision model based on outdated clinical pathway in NExUS and eLung cohorts	

Study	Population	Intervention	Comparator	Outcomes	Follow-Up
	(cetuximab) not currently used for first- or second-line NSCLC				
<b>Key</b>	<ol style="list-style-type: none"> <li>Intended use population unclear</li> <li>Clinical context for test is unclear</li> <li>Study population unclear</li> <li>Study population not representative of intended clinical use</li> <li>Study population is subpopulation of intended use</li> </ol>	<ol style="list-style-type: none"> <li>Classification thresholds not defined</li> <li>Version used unclear</li> <li>Not version currently in clinical use</li> </ol>	<ol style="list-style-type: none"> <li>Classification thresholds not defined</li> <li>Not compared to credible reference standard</li> <li>Not compared to other tests in use for same purpose</li> </ol>	<ol style="list-style-type: none"> <li>Study does not directly assess a key health outcome</li> <li>Evidence chain or decision model not explicated</li> <li>Key clinical validity outcomes not reported (sensitivity, specificity, predictive values)</li> <li>Reclassification of diagnostic or risk categories not reported</li> <li>Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests)</li> </ol>	<ol style="list-style-type: none"> <li>Follow-up duration not sufficient with respect to natural history of disease (TP, TN, FP, FN cannot be determined)</li> </ol>

*EGFR*: epidermal growth factor receptor; FN: false negative; FP: false positive; MALDI: matrix-assisted laser desorption ionization; MS: mass spectrometry; NSCLC: non-small-cell lung cancer; OS: overall survival; PFS: progression-free survival; TKI: tyrosine kinase inhibitor; TN: true negative; TP: true positive; VEGF: vascular endothelial growth factor.

**Table 6. Clinical Validity Study Design and Conduct Gaps for Proteomic Testing in NSCLC for Disease Prognosis**

Study	Selection	Blinding	Delivery of Test	Selective Reporting	Completeness of Follow-Up	Statistical
Taguchi et al (2007) Italian B validation set	2. Selection not random or consecutive (i.e., convenience)				Other related: • Variable response assessment times and intervals	Other related: • Sample sizes small • Impacts test of difference in multivariate analysis
Taguchi et al (2007) ECOG 3503 validation set	2. Selection not random or consecutive (i.e., convenience)					Other related: • Sample sizes small • Impacts test of difference in multivariate analysis
Amann et al (2010)	2. Selection not random nor consecutive (i.e., convenience)	None noted	Other related: • Proteomic testing not applied to <i>EGFR</i> variant status unknown population		Other related: • Variable response assessment times and intervals	Other related: • Confidence that the proteomic classifier is independent of <i>EGFR</i> variant status is limited by very small number of positive variants • Small sample sizes • Unadjusted for demographic and histologic characteristics associated with prognosis • Small sample sizes
Carbone et al (2010) Herbst et al (2005)	2. Selection not random or consecutive (i.e., convenience)				Other related: • Variable response assessment times and intervals	1. p-value not reported Other related: • Sample sizes small • Unadjusted for demographic and histologic characteristics associated with prognosis
Kuiper et al (2012)	2 Selection not random or consecutive (i.e., convenience)		3. VeriStrat classification performed at 3 time points (pretreatment, 1 and 3 wk after initiation)		Other related: • Variable response assessment times and intervals	Other related: • Sample sizes small • Unadjusted for demographic and histologic characteristics

Study	Selection	Blinding	Delivery of Test (therapy)	Selective Reporting	Completeness of Follow-Up	Statistical associated with prognosis
Akerley et al (2013)	2 Selection not random or consecutive (i.e., convenience)				Other related: • Variable response assessment times and intervals	Other related: • Small sample sizes
Gautschi et al (2013)	2. Selection not random or consecutive (i.e., convenience)				Other related: • Variable response assessment times and intervals	Other related: • Small sample sizes • OS (primary outcome) and PFS (secondary outcome) data not shown for reported multivariate analysis or stratification by trial • Adjusted analysis (sex, age, histology, disease stage, PS, smoking status) reported as no significant association between VeriStrat and tumor variant status; data not shown
Stinchcombe et al (2013)	2. Selection not random or consecutive (i.e., convenience)				Other related: • Variable response assessment times and intervals	Other related: • Small sample sizes
Keshtgarpour et al (2016)	2. Selection not random or consecutive (i.e., convenience)		Pre- and posttreatment VeriStrat scores used		Other related: • Variable response assessment times and intervals	Other related: • Small sample sizes • VeriStrat indeterminate case added to VeriStrat “good” data pool
Grossi et al (2017)	2. Participant recruitment not random from single lung cancer treatment				Other related: • Variable response assessment times and intervals	Other related: • Adjusted analyses for PFS and OS did not include age or other sensitizing

Study	Selection unit	Blinding	Delivery of Test	Selective Reporting	Completeness of Follow-Up	Statistical
						variants ( <i>EGFR</i> and <i>ALK</i> ) although data reported <ul style="list-style-type: none"> <li>• Overall sample sizes small</li> <li>• Slow accrual</li> <li>• Number of <i>EGFR</i> variant–positive and <i>ALK</i> translocation findings too small to assess correlation with VeriStrat classification</li> </ul>
Grossi et al (2018)	2. Participant selection differs between and among cohorts			2. VeriStrat classification results for 2 of 3 cohorts imported from abstract sources	Other related: <ul style="list-style-type: none"> <li>• Variable response assessment times and intervals</li> </ul>	Other related: <ul style="list-style-type: none"> <li>• Small sample sizes</li> </ul>
<b>Key</b>	1. Selection not described 2. Selection not random or consecutive (i.e., convenience)	1. Not blinded to results of reference or other comparative tests	1. Timing of delivery of index or reference test not described 2. Timing of index and comparator tests not same 3. Procedure for interpreting tests not described 4. Expertise of evaluators not described	1. Not registered 2. Evidence of selective reporting 3. Evidence of selective publication	1. Inadequate description of indeterminate and missing samples 2. High number of samples excluded 3. High loss to follow-up or missing data	1. Confidence intervals and/or p values not reported 2. No statistical test reported to compare to alternatives

OS: overall survival; PFS: progression-free survival; PS: performance status.

**Table 7. Clinical Validity Results of Proteomic Testing in NSCLC for Disease Prognosis Non-VeriStrat Assays**

Study	Study Type	N	Population	Summary of Outcomes: OS for “Good” vs “Poor” Assay	Summary of Outcomes: PFS for “Good” vs “Poor” Assay
Salmon et al (2009) Erlotinib/bevacizumab generation set <sup>c</sup>	Retro	35	Stage IIIB or IV, recurrent, nonsquamous NSCLC treated with erlotinib and bevacizumab	<b>Adjusted<sup>a</sup></b> HR of death, 1.024 (95% CI, 1.009 to 1.040; p=0.003)	
Salmon et al (2009) ECOG 3503 validation set <sup>c</sup>	Retro	82	ECOG 3503 trial patients with stage IIIB or IV or recurrent NSCLC treated with first-line erlotinib	<b>Adjusted<sup>b</sup></b> HR of death, 1.012 (95% CI, 1.003 to 1.021; p=0.012)	
Wu et al (2013) Validation set <sup>d</sup>	Retro	44	Stage IIIB or IV NSCLC failed or intolerant to chemotherapy, treated with gefitinib or erlotinib <b>Histology:</b> 79.2% adeno; 20.8% squamous	OS (predicted “good” vs predicted “poor”): HR=0.357 (95% CI, 0.186 to 0.688; p=0.002)	PFS (predicted “good” vs predicted “poor”): HR=0.06 (95% CI, 0.022 to 0.016; p<0.001)
Yang et al (2015) Validation set <sup>e</sup>	Retrospective	12 3	Stage IIIB or IV NSCLC with a known <i>EGFR</i> variant status <b>Variant status:</b> 42.3% with <i>EGFR</i> -TKI-sensitive variant; 57.7% with <i>EGFR</i> WT <b>Previous <i>EGFR</i> treatment:</b> 67.5% (30.9% as first-line, 26.8% as second-line, 9.8% as third-line or greater)	Following <i>EGFR</i> -TKI treatment (81 patients in validation set): OS=29.0 mo for assay “mutant” and 28.0 mo for assay “wild” (p=NS)	Following <i>EGFR</i> -TKI treatment (81 patients in validation set): PFS=10.0 mo for assay “mutant” and 2.3 mo for assay “wild” (p<0.001)

adeno: adenocarcinoma; CI: confidence interval; ECOG: European Cooperative Oncology Group; *EGFR*: epidermal growth factor receptor; HR: hazard ratio; NSCLC: non-small-cell lung cancer; OS: overall survival; PFS: progression-free survival; TKI: tyrosine kinase inhibitor; WT: wild-type.

<sup>a</sup> Adjusted based on age, sex, histology.

<sup>b</sup> Adjusted based on metastatic site and performance status.

<sup>c</sup> Test based on 11 *m/z* features.

<sup>d</sup> Test based on 3 peptides/proteins.

<sup>e</sup> Test based on 5 peptides/proteins.

*Proteomic Testing in NSCLC to Predict Response to Therapy*

No studies were identified that used VeriStrat proteomic testing to inform therapeutic options for patients with stage I or II NSCLC if surgery or surgery plus radiotherapy had been completed or who were upstaged as a result of surgical findings.

No studies were identified that used VeriStrat proteomic testing to inform therapeutic options for patients with stage I or II NSCLC who were considered medically inoperable.

Based on the association between VeriStrat status and outcomes in patients treated with *EGFR* TKIs, it was postulated that VeriStrat testing might predict response to *EGFR* TKIs.

No studies were identified that used VeriStrat proteomic testing to predict response to first-line targeted therapies or first-line chemotherapy in patients with newly diagnosed advanced NSCLC.

In the largest study to evaluate the VeriStrat test as a predictor of therapy response (the PROSE trial), Gregorc et al (2014) prospectively evaluated the VeriStrat test in a randomized controlled trial (RCT) comparing erlotinib with chemotherapy as second-line treatment for patients with stage IIIB or IV

NSCLC, stratified by performance status, smoking history, treatment center, and (masked) pretreatment VeriStrat classification.

In a multivariable model to predict OS, which included clinical characteristics and *EGFR*-variant status, VeriStrat® classification was significantly associated with OS (HR for VeriStrat® “good” vs “poor”: 1.88; 95% CI 1.25 to 2.84; P=0.003).

In the entire analysis cohort, median overall survival was 9.0 months in the chemotherapy group and 7.7 months in the erlotinib group, and OS did not differ significantly by treatment group in adjusted or unadjusted analyses. Moreover, PFS did not differ significantly by treatment group in unadjusted analysis, but was improved for the chemotherapy group in adjusted analysis (HR 1.35; 95% CI 1.05 to 1.73; P=0.020). Stratification of patients by VeriStrat® classification changed the estimate of effect of chemotherapy. In the VeriStrat® “good” group, there was no significant difference in OS between the two treatment groups, whereas in the VeriStrat® “poor” group, OS was shorter for patients treated with erlotinib (see Table 8-10).

The authors of the PROSE trial concluded that the VeriStrat® proteomic test predicted differential benefit for erlotinib compared with chemotherapy for second-line treatment of NSCLC, suggesting that patients classified as VeriStrat® “poor” would have better outcomes with chemotherapy than erlotinib.

Peters et al (2017) published a randomized phase 2, open-label trial (EMPHASIS trial) exploring the differential effect of second-line erlotinib vs docetaxel in VeriStrat “good” vs VeriStrat “poor” patients. Patients had stage IIIB or IV squamous cell NSCLC and had failed first-line platinum-based doublet chemotherapy. Recruitment for the trial ended early due to low enrollment and the release of results from other trials (e.g., PROSE). The investigators performed an analysis of the findings from EMPHASIS and conducted an exploratory analysis combining results with those from the squamous cell NSCLC cohort in the PROSE trial. Eighty patients were randomized, of whom 58 (72.5%) were categorized as VeriStrat “good.” The primary end point was PFS and was analyzed on an intention-to-treat basis. After a median follow-up of 20.5 months, 73 patients had experienced disease progression (median PFS, 2.7 months). Median PFS was 1.6 months in the erlotinib group and 3.0 months in the docetaxel group; the difference between groups was not statistically significant (p=0.37). PFS did not differ significantly by VeriStrat status, and there was no significant interaction between treatment and VeriStrat status (p=0.80). These study characteristics and results, as well as results for the secondary outcome OS, are presented in Tables 8 to 10. This study was restricted to squamous NSCLC histology, and the treatment decision model is not representative of current recommendations.

Several retrospective analyses of data from RCTs evaluating the efficacy of TKIs have examined VeriStrat® as a prognostic and/or predictive test. Carbone et al (2012) investigated the prognostic and predictive effects of VeriStrat® classification on response to treatment and survival in a subset of patients enrolled in a Phase III clinical trial of erlotinib versus placebo. BR.21, a randomized placebo-controlled study of erlotinib, enrolled 731 previously treated patients with advanced NSCLC. In the primary study, PFS and OS were prolonged by erlotinib. *EGFR* variants were prognostic for OS, but were not predictive of erlotinib benefit, while increased *EGFR* copy number variant was both prognostic and predictive of erlotinib benefit. For the present study, plasma from 441 patients was tested with the VeriStrat® test, of which 436 (98.9%) could be classified as “good” or “poor.”

Among the 144 placebo patients, VeriStrat® test results were prognostic, with “good” patients (median OS 6.6 months; 95% CI 4.4 to 8.2) surviving significantly longer than “poor” patients (median OS 3.1 months; 95% CI 2.2 to 3.7 months; HR 0.44, 95% CI 0.31 to 0.63; P<0.0001). Similar results were seen for PFS, with VeriStrat® “good” patients having longer PFS than “poor” patients (HR 0.59; 95% CI 0.42 to 0.86; P=0.002). Median survival was 10.5 months for VeriStrat® “good” patients treated with erlotinib versus 6.6 months for those on placebo (HR 0.63; 95% CI 0.47 to 0.85; P= 0.002), while in VeriStrat® “poor” patients, the median survival for erlotinib was 3.98 months and 3.09 months for placebo (HR 0.77; 95% CI 0.55 to 1.06; P= 0.11). For 252 erlotinib-treated patients with data available to evaluate for objective response, VeriStrat® “good” patients (N=157, 62%) had a significantly higher response rate than VeriStrat® “poor” patients (11.5% vs 1.1%; P=0.002). In a Cox multivariable regression model to predict OS, the interaction term between VeriStrat® status and treatment type was not statistically significant, indicating that both “good” and “poor” cohorts derived similar survival benefit from erlotinib. The authors concluded that VeriStrat® status predicted response to erlotinib, but did not predict differential benefit from erlotinib for OS or PFS.

In 2017, Gadgeel et al conducted a retrospective analysis of data from the LUX-Lung 8 trial, which compared second-line treatment with one of two TKIs: erlotinib or afatinib in patients with advanced Stage IIIB or IV squamous NSCLC. *EGFR* variant status was not considered in study eligibility. Blood samples for VeriStrat® analysis were available for 691 (87%) of 795 randomized patients; of these, 12 were indeterminate results and four could not be analyzed. The primary objective of the analysis was to evaluate whether VeriStrat® status pretreatment was associated with OS and in the afatinib vs erlotinib groups. In the cohort with VeriStrat® results (n=675), OR was significantly higher in the afatinib group (median, 7.8 months) than in the erlotinib group (median, 6.9 months; p=0.03). When stratified by VeriStrat® status, OS was significantly higher with afatinib than with erlotinib in the VeriStrat® “good” group (median, 11.5 vs 8.9 months; HR=0.79; 95% CI, 0.63 to 0.98) but not the VeriStrat® “poor” group (median, 4.7 vs 4.8 months; HR=0.90; 95% CI, 0.70 to 1.16). In the VeriStrat® stratified analysis, findings were similar for PFS. The study lacked a group receiving chemotherapy with which to compare the efficacy of TKIs.

#### Section Summary: Clinically Valid

No published studies were identified that assessed the prognostic use of VeriStrat proteomic testing in newly diagnosed stage I or II NSCLC.

For individuals with newly diagnosed advanced NSCLC without prior systemic therapy, 5 retrospective studies assessed the use of VeriStrat (“good” or “poor”) as a prognostic test to discriminate between OS (primary outcome) and PFS (secondary outcome) outcomes using available samples from previously conducted clinical trials as validation of the classification. Classification based on proteomic testing (i.e., VeriStrat “good” vs “poor”) was associated with survival outcomes in analyses that were primarily unadjusted for clinical and patient factors known to be associated with disease survival. The evidence is limited by heterogeneity in patient population characteristics such as histology and the treatment regimens used. The treatment regimens using *EGFR* TKIs represent an outdated clinical decision model. The populations studied were either unselected for *EGFR*-sensitizing variants or unknown variant status was excluded. Use of erlotinib (or other TKIs) in *EGFR* variant–negative or –unknown population is no longer an accepted treatment approach. Combination *EGFR* plus VEGF inhibition therapy is not an accepted treatment approach. The disposition of indeterminate proteomic test results was variable, and sample sizes in the classification groups were small. There is a single observational, nonrandomized study with prospective sample collection for proteomic testing before NSCLC treatment; it reported PFS as the primary outcome. This is the only



study that included a first-line treatment consistent with current guidelines-based recommendations (platinum-doublet-based chemotherapy with cisplatin or carboplatin in combination with pemetrexed). Participant recruitment was nonrandom from a single lung cancer treatment unit. Adjusted analyses for PFS and OS did not include age or other sensitizing variants (EGFR and ALK), although data was reported. Overall, sample sizes in classification groups were small and limited generalizability.

For individuals with advanced NSCLC that was recurrent or had advanced on prior systemic therapy, 3 retrospective studies assessed the use of VeriStrat (“good” or “poor”) as a prognostic test to discriminate between OS (primary outcome) and PFS (secondary outcome) outcomes using available samples from previously conducted clinical trials as validation of the classification. None of the trials from which the samples for VeriStrat proteomic classification were derived used a therapy consistent with current guidelines-based recommendations. The populations in all 3 studies were unselected for EGFR-variant status. One study used pre- and posttreatment proteomic test scores and added an indeterminate result to the “good” result data pool.

One additional retrospective study (Grossi et al [2018]) has limited evidentiary value. It combined the previously reported single prospective study cohort with results from 2 cohorts that are only referenced in abstract form.

No published studies were identified that assessed the use of VeriStrat proteomic testing to inform treatment options in newly diagnosed stage I or II NSCLC.

No published studies were identified that assessed the use of VeriStrat proteomic testing to inform treatment options for newly diagnosed advanced NSCLC patients who had not received prior systemic therapy.

The literature on the predictive value of proteomic testing consists of 2 RCTs in patients with advanced NSCLC who failed first-line chemotherapy. The 2 RCTs demonstrated that classification based on proteomic testing (i.e., VeriStrat “good” vs “poor”) is associated with survival outcomes. The evidence is limited by heterogeneity in the treatment regimens used and patient population characteristics. In the PROSE RCT, for patients classified as VeriStrat “good,” there was no significant difference in OS in the erlotinib and chemotherapy groups; however, for patients classified as VeriStrat “poor,” there was a significantly longer median OS in patients in the erlotinib group. In the EMPHASIS trial, there were no significant differences in PFS or OS among patients with VeriStrat “good” status receiving erlotinib or chemotherapy or among patients with VeriStrat “poor” status receiving erlotinib or chemotherapy. Moreover, in both the PROSE and EMPHASIS RCTs, there were no significant benefits to PFS or OS of erlotinib treatment compared with chemotherapy overall, making the application of VeriStrat in this population uncertain.

Gaps analyses for proteomic testing in NSCLC to predict response to therapy are provided in Tables 11 and 12.

**Table 8. Clinical Validity Study Characteristics of Proteomic Testing in NSCLC to Predict Response to Therapy**

Study	Study Type	N	Population	Selection Criteria	Participant Disposition
<b>Gregorc et al (2014) (PROSE)<sup>a</sup></b>	Prospective multicenter	263	Stage IIIB or IV NSCLC progressed on or were judged to be refractory to 1 prior platinum-based chemotherapy regimen randomized 1:1 to erlotinib or chemotherapy (single-agent pemetrexed or docetaxel investigator choice) <ul style="list-style-type: none"> <li>• Erlotinib arm: 134                             <ul style="list-style-type: none"> <li>○ <i>EGFR</i> WT: 79</li> <li>○ <i>EGFR</i> positive: 8</li> <li>○ <i>EGFR</i> unknown: 47</li> </ul> </li> <li>• Chemotherapy arm: 129 (74 docetaxel only, 55 pemetrexed only)                             <ul style="list-style-type: none"> <li>○ <i>EGFR</i> WT: 84</li> <li>○ <i>EGFR</i> positive: 6</li> <li>○ <i>EGFR</i> unknown: 39</li> </ul> </li> </ul>	<b>ECOG PS:</b> 0-2 (93.9% grade 0-1) <b>Histology:</b> 63.5% adeno; 17.8% squamous; 18.6% other	<ul style="list-style-type: none"> <li>• 296 patients screened</li> <li>• 285 randomized (2/11 exclusions due to “not classified as good or poor”)</li> <li>• 142 assigned to chemotherapy</li> <li>• 129 primary analysis population in chemotherapy group (13 exclusions)</li> <li>• 143 assigned to erlotinib</li> <li>• 134 primary analysis population in erlotinib arm (9 exclusions)</li> <li>• Total: 19 (7.2%) exclusions due to not starting treatment</li> <li>• Patients with controlled brain metastases could be included</li> </ul>
<b>Peters et al (2017) (EMPHAS IS-lung Trial)<sup>a</sup></b>	Prospective multicenter	80	Randomized phase 3 second-line erlotinib vs docetaxel in VS “good” vs VS “poor” <ul style="list-style-type: none"> <li>• Stage IIIB or metastatic stage IV NSCLC patients with documented progression during or after a previous line of chemotherapy (including platinum-doublet therapy)</li> <li>• Erlotinib arm: 38</li> <li>• Docetaxel arm: 42</li> </ul> Combined with Gregorc (2014) PROSE squamous cell population	<b>ECOG PS:</b> 0-2 <b>Histology:</b> squamous cell  Not described	Stage IIIB patients not amenable to radical radiotherapy were eligible: <ul style="list-style-type: none"> <li>• 94 assessed for eligibility</li> <li>• 81 randomized (1 randomized by mistake)</li> </ul> Intention-to-treat cohort: <ul style="list-style-type: none"> <li>• Erlotinib arm: 38</li> <li>• Docetaxel arm: 42</li> </ul>

adeno: adenocarcinoma; ECOG: European Cooperative Oncology Group; *EGFR*: epidermal growth factor receptor; NSCLC: non-small-cell lung cancer; PS: performance status; WT: wild-type.

<sup>a</sup> Industry sponsor or collaborator.

**Table 9. Clinical Validity Results of Proteomic Testing in NSCLC to Predict Response to Therapy**

Outcome	Median (95% CI), mo VeriStrat “Good” (n=184)	Median (95% CI), mo VeriStrat “Poor” (n=79)	HR (95% CI) VeriStrat “Good” vs “Poor”	HR (95% CI) Chemotherapy vs Erlotinib
<b>Gregorc et al (2014)</b>				
<b>OS</b>	11.0 (9.3 to 12.6)	3.7 (2.9 to 5.2)	2.5 (1.88 to 3.31; p<0.001)	<ul style="list-style-type: none"> <li>• Unadjusted HR=1.14 (0.88 to 1.49; p=0.313)</li> <li>• Adjusted HR=1.22 (0.93 to 1.59; p=0.148)</li> </ul>
<b>PFS</b>	3.4 (2.4 to 4.6)	2.0 (1.6 to 2.4)	1.75 (1.34 to 2.29; p<0.001)	<ul style="list-style-type: none"> <li>• Unadjusted HR=1.27 (0.99 to 1.62; p=0.60)</li> <li>• Adjusted HR=1.35 (1.05 to 1.73; p=0.20)</li> <li>• Median OS, 9.0 mo (6.8 to 10.9 mo) chemotherapy arm vs 7.7 mo (5.9 to 10.4 mo)</li> </ul>
	<b>VeriStrat “Good”</b>	<b>VeriStrat “Poor” (n=22)</b>		

(n=58)				
Peters et al (2017) (EMPHASIS-lung Trial)				
OS	8.2 (6.7 to 10.6)	5.2 (3.1 to 7.1)	0.49 (0.28 to 0.86; p=NR)	Median OS=7.1 mo for both erlotinib and docetaxel
PFS	NR (87% experienced a progression-defining event)	NR (100% experienced a progression defining event)	0.73 (0.44 to 1.22; p=NR)	

CI: confidence interval; HR: hazard ratio; NR: not reported; NSCLC: non-small-cell lung cancer; OS: overall survival; PFS: progression-free survival.

**Table 10. Clinical Validity Results of Proteomic Testing in NSCLC Predict Response to Therapy**

Classification	N	Chemotherapy N (%)	Erlotinib N (%)	Hazard Ratio	p
<b>Gregorc et al (2014)</b>					
VeriStrat “good”		88 (48)	96 (52)		
VeriStrat “poor”		41 (52)	38 (48)		
		Median Overall Survival (95% CI), mo	Median Overall Survival (95% CI), mo	Hazard Ratio (95% CI)	
VeriStrat “good”	184	10.9 (8.4 to 15.1)	11.0 (9.2 to 12.9)	1.05 (0.77 to 1.46, p=0.714)	
VeriStrat “poor”	79	6.4 (3.0 to 7.4)	3.0 (2.0 to 3.8)	1.72 (1.08 to 2.74, p=0.022)	
<b>Peters et al (2017)</b>					
VeriStrat “good”	58	7.8	8.4	NR	0.88
VeriStrat “poor”	22	4.4	5.2	NR	0.68

OS by treatment group stratified by VeriStrat classification in randomized controlled trial.  
CI: confidence interval; NR: not reported; NSCLC: non-small-cell lung cancer.

**Table 11. Clinical Validity Relevance Gaps for Proteomic Testing in NSCLC to Predict Response to Therapy**

Study	Population	Intervention	Comparator	Outcomes	Study
<b>Gregorc et al (2014) (PROSE)</b>	2. Table 5 reports other drug interventions used as third-line treatment without protocol information 4. Use of erlotinib (or other TKIs) in <i>EGFR</i> variant-negative or unknown population no longer accepted treatment approach	Other related: • Identity of proteins that make up the MALDI-MS features still being investigated at the time of publication		1. VeriStrat assay not used to direct clinical management Other related: • Decision model based on outdated clinical pathway • Variable response assessment times and intervals	
<b>Peters et al (2017) (EMPHASIS-lung Trial)</b>	1. Accrual terminated 3. PROSE (Gregorc et al, 2014) squamous cell cohort not described	Other related: • Identity of proteins that make up the MALDI-MS features still being investigated at		1. VeriStrat assay not used to direct clinical management Other related: • Decision model based on outdated clinical pathway for	

Study	Population	Intervention	Comparator	Outcomes	Study
		the time of publication		treatment of squamous cell histology <ul style="list-style-type: none"> <li>• Variable response assessment times and intervals</li> <li>• Incomplete data on PROSE squamous cell cohort</li> </ul>	
Key	<ol style="list-style-type: none"> <li>1. Intended use population unclear</li> <li>2. Clinical context for test is unclear</li> <li>3. Study population unclear</li> <li>4. Study population not representative of intended clinical use</li> <li>5. Study population is subpopulation of intended use</li> </ol>	<ol style="list-style-type: none"> <li>1. Classification thresholds not defined</li> <li>2. Version used unclear</li> <li>3. Not version currently in clinical use</li> </ol>	<ol style="list-style-type: none"> <li>1. Classification thresholds not defined</li> <li>2. Not compared to credible reference standard</li> <li>3. Not compared to other tests in use for same purpose</li> </ol>	<ol style="list-style-type: none"> <li>1. Study does not directly assess a key health outcome</li> <li>2. Evidence chain or decision model not explicated</li> <li>3. Key clinical validity outcomes not reported (sensitivity, specificity, predictive values)</li> <li>4. Reclassification of diagnostic or risk categories not reported</li> <li>5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests)</li> </ol>	<ol style="list-style-type: none"> <li>1. Follow-up duration not sufficient with respect to natural history of disease (TP, TN, FP, FN cannot be determined)</li> </ol>

EGFR: epidermal growth factor receptor; FN: false negative; FP: false positive; NSCLC: non-small-cell lung cancer; TN: true negative; TP: true positive.

**Table 12. Clinical Validity Study Design and Conduct Gaps for Proteomic Testing in NSCLC to Predict Response to Therapy**

Study	Selection	Blinding	Delivery of Test	Selective Reporting	Completeness of Follow-Up	Statistical
Gregorc et al (2014)						Other related: <ul style="list-style-type: none"> <li>• Included variables not explicit for adjusted PFS comparing treatment groups</li> </ul>
Peters et al (2017) (EMPHASIS-lung Trial)				Other related: <ul style="list-style-type: none"> <li>• Incomplete data on PROSE squamous cell cohort</li> </ul>		1. Confidence intervals and/or p values not reported
Key	<ol style="list-style-type: none"> <li>1. Selection not described</li> </ol>	<ol style="list-style-type: none"> <li>1. Not blinded to results</li> </ol>	<ol style="list-style-type: none"> <li>1. Timing of delivery of index or</li> </ol>	<ol style="list-style-type: none"> <li>1. Not registered</li> <li>2. Evidence of</li> </ol>	<ol style="list-style-type: none"> <li>1. Inadequate description of indeterminate</li> </ol>	<ol style="list-style-type: none"> <li>1. Confidence intervals and/or p values not</li> </ol>

2. Selection not random nor consecutive (i.e., convenience)	of reference or other comparat or tests	reference test not described	2. Timing of index and comparator tests not same	3. Procedure for interpreting tests not described	4. Expertise of evaluators not described	selective reporting	3. Evidence of selective publication	and missing samples	2. High number of samples excluded	3. High loss to follow-up or missing data	reported	2. No statistical test reported to compare to alternatives
---	---	------------------------------	--	---	--	---------------------	--------------------------------------	---------------------	------------------------------------	---	----------	--

**Table 13. Summary Characteristics of 3 Cohorts**

Cohort	Platinum	Doublet Component	Other Drug Component	N	VeriStrat		EGFR Receptor Variant Status	Included in Analysis	Excluded From Analysis
					Good	Poor			
NExUS	Cisplatin	Gemcitabine	Sorafenib	NA			NR		X
NExUS	Cisplatin	Gemcitabine	Placebo	202	136	66	NR	X	
Italian	Carboplatin	Pemetrexed	None	43	28	15	Known in Grossi et al (2017) but not included in Grossi et al (2018)	X	
Italian	Cisplatin	Pemetrexed	None	33	22	11	Known in Grossi et al (2017) but not included in Grossi et al (2018)	X	
eLung	Carboplatin	Paclitaxel	Cetuximab	79	52	27	NR	X	
eLung	Carboplatin Cisplatin	Gemcitabine Gemcitabine	Cetuximab Cetuximab	82 <sup>a</sup>	56	26	NR	X	
eLung	Carboplatin Cisplatin	Pemetrexed Pemetrexed	Cetuximab Cetuximab	42 <sup>a</sup>	34	8	NR	Subpopulation of nonsquamous histology	Subpopulation of squamous histology

Adapted from Grossi et al (2018).

EGFR: epidermal growth factor receptor; NA: not available; NR: not reported.

<sup>a</sup> Not reported separately.

### Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

### Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

The proposed clinical utility of VeriStrat is for use by physicians to predict expected survival for standard therapies in the treatment of patients with NSCLC. Clinical utility is also proposed for physicians to use VeriStrat to select patients for systemic therapy based on the presence or absence of EGFR-sensitizing variants. Direct evidence from studies that demonstrate improved outcomes for patients managed with a strategy that includes proteomic testing compared with a strategy that does not, is not available for use of proteomic testing to select targeted therapy or other systemic therapy for NSCLC. Confidence that the proteomic classifier is independent of EGFR-variant status, as well as other tumor and patient characteristics, has not been demonstrated thus VeriStrat lacks clinical validity. The identity of the proteins that make up the MALDI-MS features was still being investigated at the time of publication of the studies for both prognostic and predictive uses, further challenging the specificity for malignant biologic processes and conditions.

#### Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Absent direct evidence, a chain of evidence could be used to support the use of VeriStrat to select patients for EGFR TKI therapy. If EGFR TKI therapy were used as a standard of care in patients with unknown or negative EGFR status in the first-, second-, or third-line settings, proteomic testing could be used to select patients who are least likely to benefit. However, the IUNO trial did not find that erlotinib was efficacious in patients with NSCLC with no known EGFR variant, and the PROSE and EMPHASIS trials found that OS did not differ significantly for patients with advanced NSCLC treated with second-line erlotinib or chemotherapy. There were mixed findings on PFS in the PROSE and EMPHASIS trials. Due to study findings and the lack of support from guidelines for EGFR TKIs in this setting, EGFR TKI therapy is no longer standard therapy for any EGFR-negative or -unknown patients. Platinum-based chemotherapy and immunotherapy (based on programmed death-ligand 1 testing) guidelines-based options for previously untreated advanced EGFR-negative or -unknown patient with NSCLC or those with recurrent NSCLC or who have progressed on prior systemic therapy.

The available evidence does not demonstrate that the addition of a VeriStrat proteomic classification of “good” or “poor” to standard clinical assessment of prognosis would influence treatment or define a treatment pathway. Similarly, there is no evidence to demonstrate the impact of substitution of a VeriStrat proteomic classification in the standard of care treatment pathways. The negative predictive value of a VeriStrat “poor” score has not been demonstrated; there has been no validation in patients who received no or surgical therapy only.

Although studies of physician decision making using VeriStrat proteomic testing have been reported; they did not evaluate patient outcomes and did not evaluate the impact of EGFR testing on treatment recommendations (the number of patients who had previously received EGFR tests was not reported). Thus, these studies are insufficient to demonstrate clinical utility.

Two studies have evaluated the impact of VeriStrat testing on physician treatment recommendations. Akerley et al (2013) reported on 226 physicians who provided pre- and posttest treatment plan information for 403 VeriStrat tests, in the 262 cases where pretreatment recommendations were for erlotinib only, for those patients who were classified as VeriStrat “poor,” physicians recommended erlotinib in 13.3%. In a larger study, Akerley et al (2017) reported on 2411 physicians who received

14,327 VeriStrat test results. The investigators only included tests that were ordered for NSCLC, were ordered as the sole test, were not indeterminate, and were not ordered in patients with known EGFR-variant status. VeriStrat findings were a classification of “good” for 1950 (78.2%) patients and “poor” for 544 (21.8%) patients. After receiving the test results, physicians changed their treatment recommendations in 28.2% of the cases; within this group, 13.2% were classified as VeriStrat “good” and 81.6% as VeriStrat “poor.” Physicians initially considered treatment with an EGFR-TKI in 484 (89.0%) of 544 classified as VeriStrat “poor”; after receiving test results only, 49 (10%) were actually recommended EGFR-TKI treatment.

### Section Summary: Clinically Useful

No direct evidence for a serum proteomic test for the selection of an NSCLC treatment strategy was identified. Absent direct evidence, a chain of evidence could be developed to support the use of VeriStrat to select patients for EGFR TKI therapy. If EGFR TKI therapy were used as a standard of care in patients with EGFR-unknown or -negative status in the first-, second-, or third-line settings, proteomic testing could be used to identify patients who are least likely to benefit. However, given the evidence from the available trials and the lack of support from guidelines for EGFR TKIs in this setting, EGFR TKI therapy is no longer standard therapy for any EGFR-negative or -unknown patient. There are no studies that have directly evaluated the use of the proteomic classification to inform treatment selection based on current treatment pathways that consider other targeted therapy, chemotherapy, or immunotherapy options. Two studies by the same research group evaluated changes in treatment recommendations before and after receiving VeriStrat test results; patient outcomes were not reported.

### **Summary of Evidence**

For individuals with newly diagnosed NSCLC and EGFR-negative variant status who receive management with a serum proteomic test to predict survival and select treatment, the evidence includes retrospective studies and a prospective nonrandomized study. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. No published studies were identified that assessed the prognostic use of VeriStrat proteomic testing in newly diagnosed stage I or II NSCLC. For individuals with newly diagnosed advanced NSCLC and EGFR-negative variant status without prior systemic therapy, 5 studies have assessed the use of VeriStrat (“good” or “poor”) as a prognostic test to discriminate between overall survival (primary) progression-free survival (secondary) outcomes. All studies were retrospective and intended to validate the extent to which the VeriStrat proteomic classification correlated with overall survival or progression-free survival. Only 1 of the 5 studies reported the percentage of participants who were EGFR-negative, but it did not report outcomes based on variant status. One observational, nonrandomized study with prospective sample collection for proteomic testing before NSCLC treatment reported the percentage of participants who were EGFR-negative, but it did not report outcomes based on variant status. This was also the only study that included a first-line treatment consistent with current guideline-based recommendations—platinum-doublet-based chemotherapy plus cisplatin or carboplatin plus pemetrexed. The VeriStrat classification was not used to direct selection of treatment in any of the clinical trials from which the validation samples were derived. Disposition of populations with variant status “not reported” was generally not clear and could not be construed as “unknown” when wild-type or positive were reported. No studies were identified that used VeriStrat proteomic testing to inform therapeutic options for patients with stage I or II NSCLC if surgery or surgery plus radiotherapy have been completed or who were upstaged as a result of surgical findings. No studies were identified that used VeriStrat proteomic testing to inform therapeutic options for patients with stage I or II NSCLC who were considered medically inoperable. No studies were identified that used VeriStrat proteomic

testing to predict response to first-line targeted therapies or first-line chemotherapy in patients with newly diagnosed advanced NSCLC. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with newly diagnosed NSCLC and unknown *EGFR* variant status who receive management with a serum proteomic test to predict survival and select treatment, the evidence includes 4 retrospective studies and a prospective study. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. All study populations were either unselected for *EGFR*-variant status or status was expressly reported as unknown in conjunction with negative or positive status reports. None of the studies that reported unknown *EGFR*-variant status reported outcomes for the proteomic score based on unknown *EGFR*-variant status. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with NSCLC and *EGFR*-negative variant status and disease progression after first-line systemic therapy who receive management with a serum proteomic test to predict survival and select treatment, the evidence includes an RCT. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. No studies were identified that reported or analyzed outcomes using the proteomic test as a prognostic tool in *EGFR*-negative variant status populations. The evidence includes an RCT (PROSE) using proteomic testing to predict response to erlotinib compared with chemotherapy as second-line treatment for patients with stage IIIB or IV NSCLC, stratified by performance status, smoking history, treatment center, and (masked) pretreatment VeriStrat classification. In a multivariable model to predict overall survival, which included clinical characteristics and *EGFR*-variant status, VeriStrat classification was significantly associated with overall survival (HR for VeriStrat “good” vs “poor,” 1.88; 95% CI, 1.25 to 2.84;  $p=0.003$ ). However, 62% of the combined study population was *EGFR*-negative. Currently, the use of erlotinib in patients unselected for the presence or absence of an *EGFR*-sensitizing variant is not standard clinical practice. It is recommended that variant status is determined, if not previously ascertained, before selecting treatment after progression or recurrence. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with NSCLC and unknown *EGFR* variant with disease progression after first-line systemic therapy who receive management with a serum proteomic test to predict survival and select treatment, the evidence includes 3 retrospective studies and 2 RCTs. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. The use of VeriStrat as a prognostic test to discriminate between good and poor survival outcomes was assessed in 3 retrospective studies intended to validate the extent to which VeriStrat proteomic classification correlates with overall survival or progression-free survival. The VeriStrat classification was not used to direct treatment selection in any of the trials from which the validation samples were derived. None of the clinical trials from which the samples for VeriStrat proteomic classification were derived used a therapy consistent with current guidelines-based recommendations. The populations in all 3 studies were unselected for *EGFR*-variant status. In the PROSE RCT, using a multivariable model to predict overall survival, which included clinical characteristics and *EGFR*-variant status, VeriStrat classification was significantly associated with overall survival (HR for VeriStrat “good” vs “poor,” 1.88; 95% CI, 1.25 to 2.84;  $p=0.003$ ). However, 32.6% of the combined study population had unknown *EGFR* status. In the EMPHASIS RCT, there were no significant differences in progression-free survival or overall survival among patients with VeriStrat “good” status receiving erlotinib or chemotherapy or among patients with VeriStrat “poor” status receiving erlotinib or chemotherapy. The results of the EMPHASIS RCT were restricted to squamous NSCLC histology. Currently, the use of



erlotinib in patients unselected for the presence or absence of an *EGFR*-sensitizing variant is not standard clinical practice. It is recommended that variant status is determined, if not previously ascertained, before selecting treatment after progression or recurrence. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Clinical Input from Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from one academic medical center and two community health systems, one of which provided four responses, while this policy was under review in 2017. Input was uniform that erlotinib is not considered routine for individuals with non-small-cell lung cancer (NSCLC) who are *EGFR* negative or *EGFR* status unknown in the second-line setting. Reviewers had limited confidence that there is adequate evidence that the use of VeriStrat® to guide treatment selection will improve outcomes for individuals with NSCLC who are *EGFR* negative or *EGFR* status unknown in the second-line setting.

### **Practice Guidelines and Position Statements**

#### National Comprehensive Cancer Network (NCCN)

The NCCN guidelines on the management of non-small cell lung cancer (NSCLC; v.3.2018) recommend routine testing for *EGFR* variants in patients with metastatic non-squamous NSCLC (category 1 recommendation) and consideration for *EGFR* variant testing in patients with metastatic squamous NSCLC who were never smokers or with small biopsy specimens or mixed histology (category 2A recommendation).

Recommendations for first-line treatment for *EGFR*-positive patients with advanced or metastatic NSCLC, and *EGFR*-negative or -unknown patients as well as for patients in either category who have progressed on therapy are provided.

#### American Society of Clinical Oncology

The American Society of Clinical Oncology (2017) updated its clinical practice guidelines on systemic therapy for stage IV NSCLC. New or revised recommendations included the following recommendations: first-line treatment for patients with nonsquamous cell carcinoma or squamous cell carcinoma (without positive markers, e.g., *EGFR*, *ALK*, *ROS1*), based on programmed death-ligand 1 expression; second-line treatment in patients who received first-line chemotherapy, without prior immune checkpoint therapy based on programmed death-ligand 1 expression; as well as recommendations for those patients who cannot receive immune checkpoint inhibitor. Recommendations are included for patients with a sensitizing *EGFR* variant, for patients with disease progression after first-line *EGFR* tyrosine kinase inhibitor therapy based on the results of T790M variant testing, and for patients with *ROS1* gene rearrangement without prior crizotinib may be offered crizotinib, or if they previously received crizotinib, they may be offered chemotherapy.

The Society (2018) endorsed clinical practice guidelines from other medical associations (College of American Pathologists, International Association for the Study of Lung Cancer, Association for Molecular Pathology) addressing molecular testing for the selection of patient with lung cancer for treatment with targeted tyrosine kinase inhibitors.

### American College of Chest Physicians

American College of Chest Physicians updated its evidence-based clinical practice guidelines on the treatment of Stage IV NSCLC in 2013. Based on a review of the literature, the American College of Chest Physicians reported improved response rates, progression-free survival, and toxicity profiles with first-line erlotinib or gefitinib compared with first-line platinum-based therapy in patients with *EGFR* variants, especially exon 19 deletion and L858R. Moreover, the American College of Chest Physicians recommended “testing patients with NSCLC for *EGFR* variants at the time of diagnosis whenever feasible, and treating with first-line *EGFR*-TKIs if variant-positive.”

### **U.S. Preventive Services Task Force Recommendations**

Proteomic testing is not a preventive service.

### **Key Words:**

Proteomic Testing, VeriStrat®, matrix assisted laser desorption ionization, MALDI, mass spectrometry, Non-small cell lung cancer, NSCLC

### **Approved by Governing Bodies:**

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. The commercially available proteomic test (VeriStrat®; Biodesix) is available under of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

### **Benefit Application:**

Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

ITS: Home Policy provisions apply.

FEP: Special benefit consideration may apply. Refer to member’s benefit plan. FEP does not consider investigational if FDA approved and will be reviewed for medical necessity.

### **Current Coding:**

CPT Codes:

**81538** Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival (**Effective 01/01/16**)

### **Previous Coding:**

CPT:

**84999** Unlisted chemistry procedure (**Deleted effective 01/01/16**)

## **References:**

1. Abbatiello S, Ackermann BL, Borchers C, et al. New guidelines for publication of manuscripts describing development and application of targeted mass spectrometry measurements of peptides and proteins. Mol Cell Proteomics. Mar 2017; 16(3):327-328.
2. Akerley WL, Arnaud AM, Reddy B, et al. Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer. Curr Med Res Opin. Jun 2017; 33(6):1091-1097.
3. Akerley WL, Boucher K, Rich N, et al. A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer. Mar 2013; 79(3):307-311.
4. Akerley WL, Nelson RE, Cowie RH, et al. The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer. Curr Med Res Opin. May 2013; 29(5):517-525.
5. Amann JM, Lee JW, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol. Feb 2010; 5(2):169-178.
6. Auliac JB, Chouaid C, Greillier L, et al. Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study. Lung Cancer. Sep 2014; 85(3):415-419.
7. Biodesix. VeriStrat proteomic test. 2018; Available at: [www.biodesix.com/veristrat/](http://www.biodesix.com/veristrat/).
8. Bozinovski S, Uddin M, Vlahos R, et al. Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A. Jan 17 2012; 109(3):935-940.
9. Carbone DP, Ding K, Roder H, et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. J Thorac Oncol. Nov 2012; 7(11):1653-1660.
10. Carbone DP, Salmon JS, Billheimer D, et al. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer. Sep 2010; 69(3):337-340.
11. Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. Jul 2009; 4(7):792-801.
12. Cienas S, Geater SL, Petrov P, et al. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Lung Cancer. Dec 2016; 102:30-37.
13. Ciuleanu T, Stelmakh L, Cienas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. Mar 2012; 13(3):300-308.
14. College of American Pathologists, International Association for the Study of Lung Cancer, Association for Molecular Pathology (CAP, IASLC, AMP). Molecular testing guidelines for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. 2013; Available at: [www.nccn.org/professionals/physician\\_gls/f\\_guidelines.asp#site](http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site).
15. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst. Mar 3 2004; 96(5):353-356.

16. Fidler MJ, Fhied CL, Roder J, et al. The serum-based VeriStrat(R) test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. Mar 20 2018; 18(1):310.
17. Filippin-Monteiro FB, de Oliveira EM, Sandri S, et al. Serum amyloid A is a growth factor for 3T3-L1 adipocytes, inhibits differentiation and promotes insulin resistance. Int J Obes (Lond). Aug 2012; 36(8):1032-1039.
18. Gadgeel S, Goss G, Soria JC, et al. Evaluation of the VeriStrat(R) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer. Jul 2017; 109:101-108.
19. Garassino MC, Martelli O, Broggin M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumors (TAILOR): a randomised controlled trial. The Lancet Oncology. 2013; 14(10):981-988.
20. Gautschi O, Dingemans AM, Crowe S, et al. VeriStrat(R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer. Jan 2013; 79(1):59-64.
21. Gregorc V, Novello S, Lazzari C, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol. Jun 2014; 15(7):713-721.
22. Grossi F, Genova C, Rijavec E, et al. Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy. Lung Cancer. Mar 2018; 117:64-69.
23. Grossi F, Rijavec E, Genova C, et al. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy. Br J Cancer. Jan 03 2017; 116(1):36-43.
24. Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. Oct 20 2017; 35(30):3484-3515.
25. Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. Apr 10 2005; 23(11):2544-2555.
26. Hornberger J, Hirsch FR, Li Q, et al. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial. Lung Cancer. May 2015; 88(2):223-230.
27. Jacot W, Lhermitte L, Dossat N, et al. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes. J Thorac Oncol. Aug 2008; 3(8):840-850.
28. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. Mar 20 2018; 36(9):911-919.
29. Karampeazis A, Voutsina A, Souglakos J, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer. Aug 1 2013; 119(15):2754-2764.
30. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. May 20 2011; 29(15):2121-2127.

31. Keshtgarpour M, Tan WS, Zwanziger J, et al. Prognostic value of serum proteomic test and comorbidity index in diversified population with lung cancer. Anticancer Res. Apr 2016; 36(4):1759-1765.
32. Kotani K, Koibuchi H, Yamada T, et al. The effects of lifestyle modification on a new oxidized low-density lipoprotein marker, serum amyloid A-LDL, in subjects with primary lipid disorder. Clin Chim Acta. Nov 2009; 409(1-2):67-69.
33. Kuiper JL, Lind JS, Groen HJ, et al. VeriStrat((R)) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib. Br J Cancer. Nov 20 2012; 107(11):1820-1825.
34. Lazzari C, Spreafico A, Bachi A, et al. Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Oncol. Jan 2012; 7(1):40-48.
35. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. May 1 2013; 105(9):595-605.
36. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. Jul 2013; 8(7):823-859.
37. Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. Oct 20 2015; 33(30):3488-3515.
38. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2018.  
[www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf).
39. Nelson RE, Stenehjem D, Akerley W. A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Lung Cancer. Dec 2013; 82(3):461-468.
40. Peters S, Stahel RA, Dafni U, et al. Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first-line platinum-based doublet chemotherapy stratified by VeriStrat good versus VeriStrat poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. J Thorac Oncol. Apr 2017; 12(4):752-762.
41. Research OoCCP. What is Cancer Proteomics? //proteomics.cancer.gov/.
42. Salmon S, Chen H, Chen S, et al. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol. Jun 2009; 4(6):689-696.
43. Santoso A, Kaniawati M, Bakri S, et al. Secretory phospholipase A2 Is associated with the odds of acute coronary syndromes through elevation of serum amyloid-A protein. Int J Angiol. Mar 2013; 22(1):49-54.
44. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. Jun 20 2013; 368(25):2385-2394.
45. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2005; 353(2):123-132.
46. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. May 2013; 143(5 Suppl):e341S-368S.
47. Stinchcombe TE, Roder J, Peterman AH, et al. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the

- combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer. *J Thorac Oncol.* Apr 2013; 8(4):443-451.
48. Sun W, Hu G, Long G, et al. Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis. *Curr Med Res Opin.* Jul 9 2014:1-7.
  49. Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Lung and Bronchus Cancer. n.d.; Available at: [seer.cancer.gov/statfacts/html/lungb.html](http://seer.cancer.gov/statfacts/html/lungb.html).
  50. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. *J Natl Cancer Inst.* Jun 6 2007; 99(11):838-846.
  51. Wang DX, Liu H, Yan LR, et al. The relationship between serum amyloid A and apolipoprotein A-I in high-density lipoprotein isolated from patients with coronary heart disease. *Chin Med J (Engl).* Oct 2013; 126(19):3656-3661.
  52. Wheatley-Price P, Blackhall F, Lee SM, et al. The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. *Ann Oncol.* Oct 2010; 21(10):2023-2028.
  53. Wu X, Liang W, Hou X, et al. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. *Onco Targets Ther.* 2013; 6:1481-1491.
  54. Yang L, Tang C, Xu B, et al. Classification of epidermal growth factor receptor gene mutation status using serum proteomic profiling predicts tumor response in patients with stage IIIB or IV non-small-cell lung cancer. *PLoS One.* 2015; 10(6):e0128970.

### **Policy History:**

Medical Policy Panel, October 2014

Medical Policy Group, October 2014 (1): New policy, previously only listed on the Investigational Listing; remains investigational

Medical Policy Administration Committee, November 2014

Available for comment October 24 through December 7, 2014

Medical Policy Panel, October 2015

Medical Policy Group, October 2015 (3): 2015 Updates to Description, Key Points, Governing Bodies, Coding & References; no change in policy statement

Medical Policy Group, November 2015: 2016 Annual Coding Update. Created previous coding section and moved cpt 84999 to this section.

Medical Policy Group, December 2015 (4): 2016 Update to Key Points; update to literature review search date.

Medical Policy Panel, February 2017

Medical Policy Group, February 2017 (3): 2017 Updates to Description, Key Points, and References; no change to policy statement.

Medical Policy Panel, November 2017

Medical Policy Group, November 2017 (3): 2017 Updates to Description, Key Points, and References; no change to Policy statement.

Medical Policy Panel, April 2018

Medical Policy Group, May 2018 (2): 2018 Updates to Title, Description, Key Points, Key Words, and References; no change to Policy Statement.

*This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current*

*medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.*

*This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.*